US20100210792A1 - Drug delivery - Google Patents

Drug delivery Download PDF

Info

Publication number
US20100210792A1
US20100210792A1 US12/448,033 US44803307A US2010210792A1 US 20100210792 A1 US20100210792 A1 US 20100210792A1 US 44803307 A US44803307 A US 44803307A US 2010210792 A1 US2010210792 A1 US 2010210792A1
Authority
US
United States
Prior art keywords
drug
polymer
cysc
moiety
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/448,033
Other languages
English (en)
Inventor
David Taft
Steven Bitler
Qiang Zheng
Adam Bell
Stelios Tzannis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lifecore Biomedical Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/448,033 priority Critical patent/US20100210792A1/en
Assigned to LANDEC CORPORATION reassignment LANDEC CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BITLER, STEVEN, DR., ZHENG, QIANG, DR., TAFT, DAVID, DR., TZANNIS, STELIOS, DR., BELL, ADAM WARWICK, DR.
Assigned to LANDEC CORPORATION reassignment LANDEC CORPORATION CORRECTIVE ASSIGNMENT TO CORRECT THE ONE APPLICATION PREVIOUSLY RECORDED (NO. 60837234 "WIDGET DISTRIBUTION") SHOULD BE DELETED. IT WAS ACCIDENTLY ADDED. PREVIOUSLY RECORDED ON REEL 023140 FRAME 0327. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: BITLER, STEVEN, DR., ZHENG, QIANG, DR., TAFT, DAVID, DR., TZANNIS, STELIOS, DR., BELL, ADAM, DR.
Publication of US20100210792A1 publication Critical patent/US20100210792A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to polymeric systems for the delivery of drugs.
  • the desired rate may be, for example, a steady rate over a relatively long period of time, and/or a relatively rapid rate over a relatively short period of time (“bolus” delivery).
  • CYSC polymers an abbreviation for crystallizable side chain polymers
  • CYSC polymer (an abbreviation for crystalline side chain polymer) is defined herein as a polymer which
  • the moieties Y ch , Y term , b and Cy can be of any kind, and in CYSC polymers containing more than one moiety of formula (1) and/or more than one moiety of formula (2), Y ch , Y term , b and Cy can be the same or different. A wide variety of such moieties are described below.
  • the CYSC polymer can optionally contain, in addition to the moieties of formula (1) and (2), repeating units and/or terminal units having a different formula.
  • Y ch can be a
  • Y term can be a—CH 2 —CH 2 — moiety
  • b can be a —CO 2 — moiety
  • Cy can be an n-alkyl moiety containing 18 carbon atoms.
  • —Y— can be Y ch or Y term .
  • a drug associated with a CYSC polymer can for example be delivered at a controlled rate and/or at a desired location, the rate and/or the location being influenced for example by a chemical and/or physical condition which modifies the association of the drug and the CYSC polymer.
  • the condition can for example be an environment which causes the CYSC polymer to undergo a chemical change (for example the weakening or creation of any kind of chemical association, e.g. oxidation, reduction or hydration) and/or a change in physical state (for example the weakening or creation of any kind of physical association, e.g. a change in viscosity resulting from melting or crystallization, for example caused by internal or external heating) including an environment having a particular pH range, the presence of an enzyme.
  • a chemical change for example the weakening or creation of any kind of chemical association, e.g. oxidation, reduction or hydration
  • a change in physical state for example the weakening or creation of any kind of physical association, e
  • controlled rate includes, but is not limited to, a continuous, sustained rate, an increasing or decreasing rate, continuous or discontinuous release, or maintenance of a substantially constant rate.
  • the drug may be released, for example, with zero-, first- or second-order release kinetics.
  • composition comprising a CYSC polymer and a drug associated therewith.
  • the composition is a pharmaceutical formulation (alternatively referred to herein as a “formulation” or “drug formulation” or “dosage form”) comprising a CYSC polymer and a drug, wherein the formulation is suitable for administration to a human being or other mammal or a composition which can be converted into such a formulation.
  • the CYSC polymer and the formulation may be, for example, sterile or sterilizable, and/or biocompatible.
  • novel methods of controlling the release of a drug from a composition as defined above may comprise subjecting the composition to conditions which affect the (i.e. decrease, increase or maintain substantially constant) the strength of the association between the drug and the CYSC polymer in at least part of the composition, for example at an exposed surface of the composition.
  • Novel methods which make use of a CYSC polymer and a drug associated therewith, for example to improve or preserve the health of a mammal or cell, or to assist in the diagnosis of a mammal or cell.
  • Novel methods of treating a mammal or cell which comprise administering a CYSC polymer and a drug to the mammal or cell, the polymer and drug being associated with each other before administration or becoming associated with each other during or after administration.
  • Novel methods of making a composition as defined in (1) are often made before the composition is administered, but the invention includes embodiments in which the composition is made or modified during administration and/or in situ in the mammal or cell as a result of simultaneous or sequential administration of the CYSC polymer and the drug.
  • the methods of making the composition involve mixing a drug and a CYSC polymer, in some embodiments specifically without the presence of a liquid (or solvent).
  • the CYSC polymer is at a temperature above its melting temperature but, below a temperature which would harm the drug (by denaturing it or affecting it in some way which would substantially reduce its activity or produce degradation products that would reduce its short-term or long-term stability.
  • the mixing is carried out in the presence of a liquid (which liquid may be a solvent for one or other or both or neither of the drug and the polymer).
  • the liquid can be for example, water, an aqueous solvent, a non-aqueous solvent (e.g. an aliphatic, aromatic or mixed aliphatic/aromatic organic solvent), a polar solvent, or a non-polar solvent.
  • the CYSC polymers can often be designed to melt over a relatively narrow temperature range and at a desired temperature between 10 and 120° C. (as measured on a differential scanning calorimeter (DSC) as described below). Furthermore, it is possible to obtain similar melting characteristics over a relatively wide range of molecular weight.
  • the melting point can for example be about 30° C., about 35° C., about 37° C., about 40° C., about 45° C., about 50° C., about 55° C., about 60° C., about 65° C., about 70° C., about 75° C., or about 80° C.
  • the melting point of a composition comprising a CYSC polymer and a drug will often be different from, generally lower than, the melting point of the CYSC polymer.
  • the composition preferably has a melting temperature below 37° C., so that the composition, once implanted, maintains a non-solid consistency.
  • the relatively low melting point and narrow melting range of many CYSC polymers is particularly useful for making compositions containing a drug which is adversely affected by exposure to elevated temperatures and/or to solvents.
  • elevated temperatures can be harmful to the activity and/or the stability (short or long term) of many drugs and other drugs (for example but not limited to, proteins), and many solvents are known to have deleterious effects on drugs or on mammal or cells to which the compositions are administered, e.g. toxicity to mammals.
  • the present invention allows low temperature mixing of a drug and polymer, often without using a solvent.
  • compositions comprising a CYSC polymer and a drug drug associated therewith.
  • Such devices can for example comprise a substrate coated with such a composition or with ingredients for forming such a composition, or a reservoir which acts as a depot which consists essentially of, or which contains, such a composition; or which comprises components which form such a composition before or after administration.
  • composition or device as defined above, for example, the use of such a composition or device to deliver a therapeutically effective amount of a drug to a subject in a sustained manner over a protracted period of time, such as, for example, over at least 12 hours, over at least 24 hours or over at least 42 hours.
  • Novel methods of making devices as defined above comprising associating the drug with a CYSC polymer while the CYSC polymer is supported by a substrate, e.g. a polymeric or metal substrate.
  • Novel methods of making devices as defined above comprising contacting a substrate with a composition as defined in (1) or with components which form such a composition in situ (either after or during administration).
  • compositions as defined in (1) which are formed in an mammal or cell after separate delivery to the mammal or cell of (i) a composition comprising the drug and (ii) a composition comprising the CYSC polymer.
  • Methods which comprise administering to an mammal or cell, simultaneously or sequentially, (i) a composition comprising a drug and (ii) a composition comprising a CYSC polymer.
  • Methods of treating a composition as defined in (1) which reduce the rate at which drug is delivered from the composition when it is first exposed for example by washing the surface of a solid shaped composition with a suitable organic or inorganic solvents, for example water.
  • a pharmaceutical formulation comprising a drug and a CYSC polymer as hereinbefore defined.
  • the CYSC polymer can for example comprise a plurality of Y(Rc) moietys and have a heat of fusion of at least 10 J/g.
  • the CYSC polymer can for example one or more Rc moieties, the moiety or each of the moieties if there is more than one, comprising a polymethylene moiety containing 11 to 49 methylene moieties.
  • the CYSC polymer can for example be selected from the group consisting of: a poly-acrylate, a poly-methacrylate, a poly-alkyl-methacrylate, an poly-N alkyl methacrylamide, a poly-alkyl-acrylate, a poly-fluoroacrylate, a poly-N-alkyl acrylamide, a poly-alkyl oxazoline, a poly-alkyl vinyl ether, a poly-alkyl 1,2-epoxide, a poly-alkyl glycidyl ether, a poly-vinyl ester, a poly-acrylamide, a poly-methacrylamide, a poly-maleimide, a poly- ⁇ -olefin, a poly-p-alkyl styrene, a poly-alkylvinyl ethers, a polyether, a polyester, a polyurethane, a polysilane, a polysiloxane,
  • CYSC polymer can for example comprise a Rc moiety which comprises an n-alkyl moiety containing 14, 16, 18, 20, 22, 30, 40 or 50 carbon atoms.
  • the CYSC polymer can for example comprise units derived from one or more monomers selected from the group consisting of: dimethylaminoethyl methacrylate, diethylaminoethyl methacrylate, t-butyl acrylamide, dimethylaminopropyl methacrylamide, N-isopropyl acrylamide, acrylonitrile, methacrylonitrile; N,N-dialkyl amino (in particular, dimethylamino) (meth)acrylates; ammonium salt-containing (meth)acrylates, for example 2-trimethylammonium methylmethacrylate chloride, methacrylamidopropyl trimethylammonium chloride, N,N-(diethyl or dimethyl)aminoethyl(meth)acrylate methosulfate; N-
  • methoxyethyl (meth)acrylate 1-acryloxy-2-hydroxy-3-phenoxypropane; methylol methacrylate; ethoxyethyl (meth)acrylate; 2-(2-ethoxyethoxy)ethylacrylate; acetoacetoxyethyl (meth)acrylate; phenoxyethyl (meth)acrylate; (meth)acrolein; alkoxy or hydroxyl (polyoxyalkylene) alkyl (meth)acrylates, e.g.
  • methoxy- or hydroxypolyoxyethylene (meth)acrylates methoxy- or hydroxypolyoxyethylene (meth)acrylates, alkoxy- or hydroxypolyoxypropylene-polyoxyethylene alkyl (meth)acrylates, trifluoroethyl (meth)acrylate, heptadecafluorodecyl (meth)acrylate, octafluoropentyl (meth)acrylate, eicosafluoroundecyl (meth)acrylate, hexadecafluorononyl (meth)acrylate, tetrahydroperfluorodecyl (meth)acrylate; trimethylsiloxy ethyl(meth)acrylate, 3-acryloxypropyl trimethoxysilane, and 3-acryloxypropyl tris(trimethylsiloxy)silane, monomethacryloxymonotrimethylsiloxyterminated polyethylene oxide, and monomethacryloxypropyl al
  • the CYSC polymer can for example contain repeating units of formula Z(Rz) as hereinafter defined, and optionally such repeating units include functionalized moieties.
  • the CYSC polymer can for example have a Tp ⁇ To ⁇ Tp 0.7 .
  • the CYSC polymer can for example have a Mn molecular weight of between 1,000 Daltons and 100,000 Daltons.
  • the CYSC polymer can for example have a Tp of between 38° C. and 60° C.
  • the CYSC polymer can for example comprise hydrolytically labile bonds.
  • the CYSC polymer can for example be free of mainchain crystallinity.
  • the CYSC polymer can for example be a polymer other than a block copolymer or graft copolymer, e.g.
  • the CYSC polymer may or may not be a hydrogel
  • the drug can for example be associated with the polymer by one or more associations selected from electrostatic bonds, hydrogen bonds, Van der Waals forces, covalent bonds, and entropic forces.
  • the CYSC polymer can for example (i) contain one or more Rc moieties, the moiety or each of the moieties if there is more than one, comprising a polymethylene moiety containing 11 to 49 methylene moieties and (ii) have a melting temperature of not greater than 60° C.
  • the formulation can for example contain at least 5% by weight of the drug.
  • the formulation can for example include a drug selected from the group consisting of anti-pain medications, anti-psychotics, anti-inflammatories, hormones, cholesterol lowering drugs, anti-osteoporosis drugs, anti-angeogenics and contraceptives.
  • the formulation can for example include Risperidone or a pharmacologically active derivative, congener or metabolite thereof.
  • the formulation can for example include a ligand that binds specifically to a target.
  • the formulation can for example be one which, in vivo, when implanted within a subject, continuously releases a therapeutically effective dose of drug to the subject over a period of at least 30 days.
  • the formulation can for example be one which, when tested in vitro (elution into 1 L PBS, pH 7.2 at 37° C., stirred at 100 rpm), releases the drug at an the average rate of release no greater than 50 milligrams per day averaged over any 24 hour period during the first 168 hours of elution.
  • the formulation can for example be one which, when tested in vitro (elution into 1 L PBS, pH 7.2 at 37° C., stirred at 100 rpm), releases the drug at an average rate no greater than 25 milligrams per day averaged over any 24 hour period during a period from 12 hours to 168 hours following inception of elution.
  • the formulation can for example be one which, when tested in vitro (elution into 1 L PBS, pH 7.2 at 37° C., stirred at 100 rpm), continuously releases between 1 milligram and 60 milligram of the drug per day over a period of at least 30 days.
  • the formulation can for example be one which, when tested in vitro (elution into 1 L PBS, pH 7.2 at 37° C., stirred at 100 rpm), continuously releases between 1 milligram and 60 milligrams of the drug per day averaged over any 24 hour period during a period from 12 hours to 168 hours following inception of elution.
  • the formulation can for example be one which, when tested in vitro (elution into 1 L PBS, pH 7.2 at 37° C., stirred at 100 rpm), releases no more than 10% by weight of the drug present in the formulation over a period of 24 hours.
  • the formulation can for example be one which, when tested in vitro (elution into 1 L PBS, pH 7.2 at 37° C., stirred at 100 rpm), continuously releases a therapeutic dose of drug over a period of at least 30 days wherein the average 24 hour drug release rate is within one standard deviation of the 30 day mean.
  • the formulation can for example be one which, in vivo, when implanted within a subject, continuously releases a therapeutic dose of drug over a period of at least 30 days.
  • a method for administering a drug to a subject comprising (1) administering to the subject a formulation as defined in (1), and (2) continuously releasing a therapeutically effective dose of the drug to the subject over a period of at least 30 days.
  • the formulation is pretreated by contacting it with a liquid, e.g. a liquid buffer, before it is administered.
  • the treatment can for example before a period of at least 30 minutes.
  • the method can for example comprise implants in the formulation within the subject, for example subcutaneously.
  • the drug is Risperidone, and the therapeutically effective dose is between 1 mg and 60 mg per day.
  • the drug is Diclofenac sodium, and the therapeutically effective dose is between 50 mg and 300 mg per day.
  • the method can for example comprise releasing the drug from the formulation at a predetermined time wherein the drug is released from the formulation by one or more of the following changes in condition
  • the formulation may release a therapeutic dose of a drug only at or above a certain pH.
  • a formulation may release little or no drug in an aqueous environment at an acid pH (such as the stomach), but release a therapeutic dose or drug at a less acid pH such as at pH6, or at an alkali pH, such as pH7, pH8, pH9, or pH10 or above.
  • acid albile drugs such as proteins or peptides that would be damaged by the acid environment of the stomach.
  • the CYSC polymer and the drug/CYSC polymer compositions used in the present invention can optionally have one or, where possible, more than one, of the following characteristics.
  • Example No. 1A 2A 3A 4A 5A 6A 7A Sample No. 328-133-1 326-1-1 326-2-1 326-3-1 326-5-1 327-1-1 327-39-1 A
  • Example No. 8A 9A 10A 11A 12A 13A 14A Sample No. 327-40-1 326-8-1 326-8-3 327-3-1 327-3-3 327- 327- A B B 137-1 137-3
  • Example No. 15A 16A 17A 18A 19A 20A Sample No. 326-6-1 326-6-3 326-9-1 326-11-3 327-42-2 327-42- 11
  • a formulation means any composition which (i) is suitable for administration to a human being or other mammal or which can be treated, e.g. sterilized, to make it suitable for such administration, and (ii) comprises at least one drug and at least one CYSC polymer.
  • a formulation may comprise additional, non-active components, such as pharmaceutical excipients, fillers, carrier materials etc that may be used to modify or improve the drug release, improve its physical and/or chemical stability, dosage form performance, processing, manufacturing, etc.
  • drug means any drug which is biologically, physiologically, or pharmacologically active, in a human being or other mammal, locally and/or systemically, and includes diagnostic agents.
  • drugs are described in well known literature references such as the Merck Index and the Physicians Desk Reference and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances which affect the structure or the function of the body; pro-drugs, which become biologically active or more active after they have been placed in a physiological environment, biologically active metabolites of drugs which become biologically active or more active once they have been produced by the metabolism of a precursor chemical; Different types of drugs which may be used with the invention are discussed in more detail later in this application.
  • Drugs suitable for use in the present invention are for example disclose in column 11, line 16, to column 12, line 58, of U.S. Pat. No. 6,297,337, and in paragraph 0045 of US 2003/0224974, the entire disclosures of which are incorporated by reference herein for all purposes.
  • mammal or cell encompasses, but is not limited to, human beings and other mammals, and living tissue which is not part of a mammal.
  • terapéuticaally effective amount means an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent, effective to facilitate a desired therapeutic effect.
  • the precise desired therapeutic effect will vary according to the condition to be treated, the formulation to be administered, and a variety of other factors that are appreciated by those of ordinary skill in the art.
  • diagnostic agent means any chemical moiety that may be used for diagnosis or in a diagnostic test.
  • diagnostic agents include imaging agents containing radioisotopes, contrasting agents containing for example iodine, enzymes, fluorescent substances and the like.
  • treatment means the application of a process to an individual in order to alter a physiological state, whether or not the process includes a curative element.
  • the dosage form is placed in physiological buffered saline at a physiological pH and a physiologically relevant temperature, e.g. about 25° C. or 37° C.; preferably between 32° C. and 37 C.
  • physiological buffered saline at a physiological pH and a physiologically relevant temperature, e.g. about 25° C. or 37° C.; preferably between 32° C. and 37 C.
  • the amount of drug released and the time over which it is released in an in vitro test is no more than an indicator of in vivo results, but is useful for making comparative measurements.
  • Controlled release of a drug means release of the drug in a pre-determined or adjustable way such that the amount or rate or timing of release is pre-set or is altered in a desired way.
  • sustained release of a drug means release over an extended period of time, for example minutes, hours or days, such that less than all the drug is released initially.
  • a sustained release rate may provide, for example, a release of a certain specified amount of a drug from a dosage form, over a certain time period, under physiological conditions or in an in vitro test.
  • “Bolus” release means release of a large dose, for example all of a drug at one time or over a short period of time. Bolus release can be preceded or followed by sustained release.
  • burst effect as used in the context of drug delivery during administration of a drug means the release of drug from a dosage form as a bolus at higher than desired level or rate, typically, exceeding the therapeutically effective level.
  • a burst effect may be defined as the release of more than 50% of a drug from a dosage form under specific experimental conditions, such as when the dosage form is placed in physiological buffered saline at a set temperature such as at about 25° C. or 37° C.
  • a burst is generally followed by a rapidly decreasing rate of release.
  • a burst effect may be characterized by the release of a certain defined amount of a drug from a dosage form under specific conditions.
  • a burst effect may be defined as the release of a defined threshold amount of the total amount of loaded drug over a defined time under physiological conditions (in normal intended use, e.g. gastrointestinally for a pill or subcutaneously for an implant) or in a suitable in vitro test for example as described above or as described in the Examples below.
  • the threshold amount may be at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the total amount of drug loaded into the dosage form
  • the defined time can be for example, 30 minutes, 1 hour, 2 hours, 3, hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 24 hours, 36 hours, or 48 hours.
  • a dosage form that does not display a significant burst effect may be a dosage form that, for example, releases less than 10% of the total amount of drug loaded into the dosage form over a 3 hour period following implantation.
  • the dosage form is pre-treated prior to implantation so that any burst effect is spent before implantation.
  • controlled release device means any formulation or device wherein the release rate (e.g., rate of timing of release) of a drug or other desired substance contained therein is controlled by the device or dosage form itself and/or by the environment of use.
  • Controlled drug delivery includes delivery of an amount of drug to a particular target site at a particular time, for example delivery of a bolus of drug to a tumor site.
  • drug delivery device means any device that can deliver a drug, including pills, capsules, gels, depots, medical implantable devices (e.g., stents, including self-expanding stents, balloon-expandable stents, drug-eluting stents and stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, endocardial leads, bioerodable implants and the like, and externally manipulated devices (e.g. drug devices and catheters, including catheters which can release a drug, e.g. as a result of heating the tip of the catheter).
  • medical implantable devices e.g., stents, including self-expanding stents, balloon-expandable stents, drug-eluting stents and stent-grafts, grafts (e.g., aortic graf
  • dosage form means a composition which comprises a drug compounded or processed or presented in such a way that it is suitable for administration to a subject.
  • a dosage form comprises a CYSC polymer and, a drug, and may also include one or more other additives, for example pharmaceutically acceptable excipients, carriers, penetration enhancers, stabilizers, buffers or other materials physically associated with the drug and/or the CYSC polymer to enhance the deliverability of the dosage form and/or the effectiveness of the drug.
  • a dosage form may be administered, for example, as a liquid, a suspension, a solid such as a tablet, pill, capsule (including a microcapsule), emulsion, micelle, ointment, gel, emulsion, depot (including a subcutaneously implanted depot), or coating on an implanted device, e.g. a stent or the like.
  • the dosage form can for example be applied externally, e.g. as a patch, or a device applied partly externally and partly implanted, or completely implanted or injected subcutaneously.
  • association means any type of interaction, including chemical bonds (including, for example, covalent, ionic and hydrogen bonds) and/or Van der Waals forces, and/or polar and non-polar interaction through other physical constraints provided by molecular structure, and interactions through physical mixing.
  • “Patterned” or “temporal” as used in the context of drug delivery means delivery of drug in a pattern, generally a substantially regular pattern, over a pre-selected period of time (e.g., other than a period associated with, for example a bolus injection). “Patterned” or “temporal” drug delivery includes delivery of drug at an increasing, decreasing, substantially constant, or pulsatile, rate or range of rates (e.g., amount of drug per unit time, or volume of drug formulation for a unit time), and further includes delivery that is continuous or substantially continuous, or chronic.
  • a chemical compound including a polymer
  • a functional moiety i.e. a moiety which will undergo a further desired chemical reaction
  • the polarity of the compound is changed, as evidenced, for example, by a change in the solubility parameter.
  • alkyl is used in this specification to include alkyl moieties which are straight chain alkyl moieties, branched chain alkyl moieties, cycloalkyl moieties, and moieties which consist essentially of two or more of straight chain alkyl, branched chain alkyl and cycloalkyl moieties.
  • melting point (often abbreviated to Tp or Tm)
  • onset of melting temperature (often abbreviated to To)
  • heat of fusion (which is a measure of crystallinity of the polymer, is expressed in J/g and is often abbreviated to ⁇ H).
  • Tp, To and ⁇ H determined using a differential scanning calorimeter (hereinafter DSC), e.g. a Q 100 DSC from TA Instruments at a rate of temperature change of 10° C./min, e.g. from ⁇ 10 to 150° C.
  • DSC differential scanning calorimeter
  • Tp is the peak melting temperature
  • To is the temperature at the intersection of the baseline of the DSC peak and the onset line, the onset line being defined as the tangent to the steepest part of the DSC curve below Tp.
  • the values of Tp, To and ⁇ H are measured on the second heat cycle.
  • Solubility parameters given herein were calculated using methods described in D. W. Van Krevelen “Properties of Polymer”, Elsevier, 1997, 200-214, especially 214, and are expressed in units of J 1/2 /cm 3/2 .
  • Cx a linear moiety containing x carbon atoms, optionally directly linked to each other.
  • CxA an n-alkyl acrylate in which the n-alkyl group contains x carbon atoms, e.g. C16A is hexadecyl acrylate.
  • CxMA an n-alkyl methacrylate in which the n-alkyl group contains x carbon atoms, e.g. C16MA is hexadecyl methacrylate.
  • Acrylic acid MA Methacrylic acid
  • AIBN Azobisisobutyronitrile DMAEA dimethylaminoethyl acrylate
  • DMAEMA dimethylaminoethyl methacrylate
  • PEG6A CH 2 ⁇ CH—CO—O—(CH 2 CH 2 O) 6 H
  • compositions comprising and grammatical equivalents thereof are used in this specification to mean that, in addition to the features specifically identified, other features are optionally present.
  • a composition “comprising” (or “which comprises”) ingredients A, B and C can contain only ingredients A, B and C, or can contain not only ingredients A, B and C but also one or more other ingredients.
  • the term “consisting essentially of” and grammatical equivalents thereof is used herein to mean that, in addition to the features specifically identified, other features may be present which do not materially alter the claimed invention.
  • the term “at least” followed by a number is used herein to denote the start of a range beginning with that number (which may be a range having an upper limit or no upper limit, depending on the variable being defined).
  • At least 1 means 1 or more than 1
  • at least 80% means 80% or more than 80%.
  • the term “at most” followed by a number is used herein to denote the end of a range ending with that number (which may be a range having 1 or 0 as its lower limit, or a range having no lower limit, depending upon the variable being defined).
  • at most 4 means 4 or less than 4
  • at most 40% means 40% or less than 40%.
  • “from 8 to 20 carbon atoms” or “8-20 carbon atoms” means a range whose lower limit is 8 carbon atoms, and whose upper limit is 20 carbon atoms.
  • the terms “plural”, “multiple”, “plurality” and “multiplicity” are used herein to denote two or more than two features.
  • first and second features this is generally done for identification purposes; unless the context requires otherwise, the first and second features can be the same or different, and reference to a first feature does not mean that a second feature is necessarily present (though it may be present).
  • a composition which comprises a CYSC polymer and a drug the composition can comprise two or more CYSC polymers and/or two or more drugs.
  • two or more features this includes the possibility that the two or more features are replaced by a lesser number or greater number of features providing the same function (except where the context excludes that possibility).
  • the numbers given herein should be construed with the latitude appropriate to their context and expression; for example, each number is subject to variation which depends on the accuracy with which it can be measured by methods conventionally used by those skilled in the art.
  • b is a bond or a divalent moiety linking the Cy moiety to an intermediate point on the polymer backbone all to a terminal moiety.
  • b may for example be a covalent bond, or a divalent organic moiety (e.g. an aliphatic, aromatic or mixed aliphatic/aromatic moiety) or inorganic moiety.
  • b moieties include ester, carbonyl, amide, amine oxide, hydrocarbon (for example phenylene), amino, ether, polyoxyalkylene, or an ionic salt linkage (for example a carboxyalkyl ammonium, sulfonium or phosphonium ion pair).
  • the Cy moieties (which provide side chains pendant from an intermediate location and/or from a terminal location of the polymer backbone) in a particular CYSC polymer may be the same or different.
  • the Cy moieties must be such that they are capable of interacting with other Cy moieties, for example other Cy moieties elsewhere on the same polymer and/or on a different polymer (which may or may not be a CYSC polymer) and/or on a non-polymeric molecule, to provide crystallinity.
  • the interaction between the Cy moieties is generally by way of hydrogen bonds or Van der Waals forces, and not via covalent or ionic bonding.
  • the Cy moieties can be of any kind, for example aliphatic, e.g. alkyl, or mixed aliphatic aromatic.
  • the CYSC polymers contain moieties such that the polymer, when examined on a DSC in the manner defined below, has a heat of fusion of at least 5 J/g and an associated distinct melting temperature resulting from crystallization of the Cy moieties.
  • Such polymers are known and have been referred to as side chain crystalline polymers (sometimes abbreviated to SCC polymers or SCCPs).
  • SCC polymers contain Cy moieties whose nature, amount and distribution are such that the polymer has a heat of fusion of at least 10, at least 20, at least 25, at least 30, at least 35, at least 40, or at least 45, for example 5-50 or 10-50, or 10-40 or 15-35 or 20-30, J/g.
  • Patents and other publications relating to SCC polymers include J. Poly. Sci. 60, 19 (1962); J. Poly. Sci, (Polymer Chemistry) 7, 3053 (1969), 9, 1835, 3349, 3351, 3367, 10, 1657, 3347, 18, 2197, 19, 1871; J. Poly. Sci, Poly-Physics Ed 18 2197 (1980); J. Poly. Sci, Macromol. Rev, 8, 117 (1974); Macromolecules 12, 94 (1979), 13, 12, 15, 18, 2141, 19, 611; JACS 75, 3326 (1953), 76; 6280; Polymer J 17, 991 (1985); and Poly. Sci USSR 21, 241 (1979); U.S. Pat. Nos.
  • the Cy moieties often comprise a linear carbon chain of at least 8 or at least 12 carbon atoms directly linked to each other, e.g. 12-50 or 16-30 carbon atoms.
  • the moiety is generally not branched, but can be branched providing that the branching does not prevent the moiety from being capable of crystallization.
  • the moiety can be unsubstituted or substituted predominantly only by fluorine atoms, or can be substituted by other moiety which do not prevent the moiety from being capable of crystallization.
  • Cy can be for example a moiety comprising 6 to 50, e.g. 12 to 50, preferably 12 to 22 or 16 to 22, substantially linear carbon atoms, e.g. a moiety comprising at least 11 methylene moieties, for example 11-49 methylene moieties and a terminal methyl moiety, or a moiety comprising at least 5, e.g. 5 to 49 linear perfluoro or substantially perfluoro methylene moieties and a terminal perfluoromethyl moiety or hydrogen atom.
  • Cy moieties include C14, C16, C18, C20, C22, C30, C40 and C50, in particular n-alkyl moieties containing 14, 16, 18, 20, 22, 30, 40 and 50 carbon atoms, and partially or fully fluorinated n-alkyl groups containing at least 8 carbon atoms, and mixtures of Cy moieties having similar average chain lengths.
  • All the moieties of the formula —Y(b-Cy)— in the CYSC polymer can be the same, or there can be a plurality of (i.e. two or more) different types of moiety which differ from each other in one or more of Y, b and Cy.
  • the different types are randomly distributed throughout the polymer.
  • the different types are distributed in a desired non-random fashion in at least part of the polymer, such as in a block copolymer or a graft copolymer.
  • the polymer can comprise at least one polymer block which comprises only one type of repeating unit of the formula —Y(Rc 1 )- and a second polymer block which comprises only repeating units of the formula —Y(Rc 2 )-.
  • the polymer may comprise one or more sections which contain a plurality of —Y(Rc 1 )- and —Y(Rc 2 )- units distributed randomly, and at least one polymer block which comprises (i) only another type of repeating unit of the formula —Y(Rc)-, or (ii) a plurality of randomly distributed different repeating units of the formula —Y(Rc)-.
  • Cy moieties When there are two or more different Cy moieties, they may have, for example, an average length of 6 to 50 linear carbon atoms, the average being calculated by adding all lengths of all the Cy moieties in the polymer (or, in the case of a block, including graft, copolymer, all the Cy moieties in the block) and dividing by the number of Cy moieties.
  • the average length may have, for example, an accuracy of +/ ⁇ 3%, +/ ⁇ 5%, or +/ ⁇ 10% or any amount therebetween.
  • Cy moieties include polyoxyalkylene, e.g. polyoxyethylene, units.
  • Such Cy moiety can for example be derived from alkoxy polyoxyalkylene(meth)acrylates, where the alkyl portion of the alkoxy group is preferably an alkyl, particularly an n-alkyl, group containing 12 to 50, preferably 12 to 22 carbons, and the polyoxyalkylene unit is a homopolymer, random copolymer, or block copolymer containing 2 to 100, e.g. 5 to 100, preferably 5 to 60, oxyalkylene units, preferably 2-20, e.g. 2-4, oxyalkylene units.
  • Such monomers include cetyl polyethoxylated methacrylate, stearyl polyethoxylated (meth)acrylate, behenyl polyethoxylated (meth)acrylate, lauryl polyethoxylated (meth)acrylate, cholesterol polyethoxylated (meth)acrylate and the like.
  • the polyoxyalkylene unit can be attached to the alkyl side chain portion, as for example in hydroxypolyalkyleneoxyalkyl (meth)acrylates with similar alkyl and polyalkyleneoxy groups as above, e.g. hydroxypolyethleneoxystearyl acrylate, hydroxypolyethyleneoxycetyl methacrylate and the like.
  • a CYSC polymer can consist essentially of the moieties of the formula —Y(Rc)- or it can also contain other repeating units of a different type. Such other repeating units can be represented by the formula
  • Z is a moiety forming part of the polymer backbone and Rz represents a monovalent moiety which is not an Rc moiety.
  • All the repeating units of the formula —Z(Rz)- can be the same, or there can be a plurality of different types of repeating unit which differ from each other in Z, or in Rz, or in both Z and Rz.
  • the moieties of the formula —Z(Rz)- can be randomly distributed throughout the polymer, or they can be distributed in a desired non-random fashion in at least part of the polymer.
  • Z(Rz) moieties in a CYSC polymer generally depresses the melting temperature and reduces the crystallinity of the CYSC polymer, to an extent which is dependent on the proportion and distribution of the Z(Rz) moieties and the nature of the Z(Rz) moieties.
  • the Z(Rz) moieties also contribute to the chemical and other characteristics of the CYSC polymer, and their presence can be valuable for this purpose. For example, many useful CYSC polymers have an amphiphilic character, with the Cy moieties providing hydrophobic characteristics and the Rz moieties providing hydrophilic characteristics.
  • the Z(Rz) moieties in a CYSC polymers can be of any kind, for example aliphatic, e.g. alkyl, or mixed aliphatic aromatic.
  • the Z(Rz) moieties can contain any suitable linking group through which they are linked to each other and to the Y(Rc) moieties.
  • the CYSC polymer can comprise sections which comprise the Z(Rz) moieties and which are polyacrylate, polymethacrylate, polyalkyl methacrylate, poly-N-alkyl acrylamide, poly-alkyl oxazoline, poly-alkyl vinyl ether, poly-alkyl 1,2-epoxide, poly-alkyl glycidyl ether, poly-vinyl ester, poly-acrylamide, poly-methacrylamide, poly-maleimide, poly- ⁇ -olefin, poly-p-alkyl styrene, poly-alkyl vinyl ether, polyolefin, polyether, polyurethane, polysilane, polysiloxane, or poly(alkyl phosphazene).
  • All the Z(Rz) moieties can be the same, or there can be two or more different Z(Rz) moieties, randomly distributed and/or arranged in a desired distribution, as for example in a block copolymer in which one of the blocks comprises essentially only one type of Z(Rz) moiety, and another of the blocks comprises essentially only another type of Z(Rz) moiety.
  • the Z moieties (which, when there are two or more different types of Z moiety, can be the same or different) can for example be derived from the addition and/or condensation polymerization of suitable monomers, e.g. acrylic, methacrylic, olefinic, epoxy or vinyl monomers.
  • the bond between Z and Rz can be any bond as described in the section discussing the bonds between Y and Rc.
  • the bond may be hydrolytically stable, unstable, labile to hydrolysis or enzymatic cleavage.
  • Suitable monomers from which Z(Rz) moieties can be derived can contain the desired Rz moieties, and/or can contain Rz precursor moieties some or all of which are converted into Rz moieties during or after the polymerization.
  • Suitable monomers are for example alkyl (e.g. 2-ethylhexyl, butyl, ethyl, methyl) (meth)acrylates, hydroxyalkyl (meth)acrylates (e.g. hydroxyethyl acrylate, hydroxyethyl methacrylate) alkoxyalkyl (meth)acrylates (e.g.
  • methoxyethyl acrylate, ethoxyethyl methacrylate), and hydroxypolyoxyalkylene (meth)acrylates e.g. -hydroxypolyoxyethylene methacrylate or acrylate where the ethyleneoxy units are from 4 to 50
  • other (meth)acrylates e.g.
  • alkyl groups are alkyl groups which are not Rc moieties, for example n-alkyl moieties containing less than 12, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 carbon atoms (e.g.
  • vinyl laurate ); and polar monomers, for example acrylic acid, methacrylic acid, itaconic acid, dimethylaminoethyl methacrylate, diethylaminoethyl methacrylate, t-butyl acrylamide, dimethylaminopropyl methacrylamide, N-isopropyl acrylamide, acrylonitrile, methacrylonitrile, maleic anhydride, monobutyl fumarate, vinyl acetate, N-vinyl pyrrolidone, and comonomers containing amine groups.
  • polar monomers for example acrylic acid, methacrylic acid, itaconic acid, dimethylaminoethyl methacrylate, diethylaminoethyl methacrylate, t-butyl acrylamide, dimethylaminopropyl methacrylamide, N-isopropyl acrylamide, acrylonitrile, methacrylonitrile, maleic anhydride, monobut
  • Rz may comprise polyoxyalkylene e.g. polyoxyethylene, moieties, for example a polyoxyalkylene moiety which links the Z moiety to an end group which is not an Rc moiety
  • the Rz moieties can for example include one or more desired functional groups, including, but not limited to, the functional groups forming part of the compounds listed below (the disclosure of those functional groups being independent of the moiety forming the remainder of the listed compound).
  • Useful Rz moieties include:
  • Nitrogen-containing side chains for example the moieties which result from the polymerization of the groups of monomers and specific monomers listed below. It is noted that the identified Rz moieties and/or the functional groups thereon can also be obtained through the use of other monomers: N,N-dialkyl amino (in particular, dimethylamino) (meth)acrylates; ammonium salt-containing (meth)acrylates, for example 2-trimethylammonium methylmethacrylate chloride, methacrylamidopropyl trimethylammonium chloride, N,N-(diethyl or dimethyl)aminoethyl(meth)acrylate methosulfate; N-vinylpyrrolidinone; imides like the ring-closed reaction products of maleic or itaconic anhydride with primary amines; 2-methacryloxy-N-ethylmorpholine; n- or t-butylacrylamide; (meth)acrylamide; dimethylaminopropyl meth
  • the formulations of the invention specifically exclude Rz side chains derived from N-vinylpyrrolidinone.
  • Oxygen-containing side chains for example the moieties which result from the polymerization of the groups of monomers and specific monomers listed below, including carboxyl- and sulfonic acid-containing monomers and salts thereof. It is noted that the identified Rz moieties and/or the functional groups thereon can also be obtained through the use of other monomers: acrylic acid, methacrylic acid; itaconic anhydride; itaconic acid; maleic anhydride; maleic acid; fumaric acid; monoesters and monoamides of fumaric acid, maleic acid, crotonic acid, and 2-acrylamido-2-methylpropane sulfonic acid (“AMPs”); vinyl sulfonic acid; hydroxyalkyl (meth)acrylates, in particular, hydroxyethyl, hydroxypropyl, and hydroxybutyl) (meth)acrylates; tetrahydrofurfuryl (meth)acrylate; glycidyl methacrylate; alkoxyalkyl
  • methoxyethyl (meth)acrylate hydroxycaprolactone acrylate; 1-acryloxy-2-hydroxy-3-phenoxypropane; methylol methacrylate; ethoxyethyl (meth)acrylate; 2-(2-ethoxyethoxy)ethylacrylate; acetoacetoxyethyl (meth)acrylate; phenoxyethyl (meth)acrylate; (meth)acrolein; alkoxy or hydroxyl (polyoxyalkylene) alkyl (meth)acrylates, e.g.
  • methoxy- or hydroxypolyoxyethylene (meth)acrylates for example those in which the moles of ethyleneoxy units are from 2 to 80, preferably 6 to 50; alkoxy- or hydroxypolyoxypropylene-polyoxyethylene alkyl (meth)acrylates, for example those in which the blocks of each oxyethylene and oxypropylene unit are present in 1/1 to 1/3 ratios whereby the amount of oxyalkylene units in each block is 5 to 100, preferably, 5 to 60 units.
  • Fluorine-containing side chains for example the moieties which result from the polymerization of the groups of monomers and specific monomers listed below.
  • Rz moieties and/or the functional groups thereon can also be obtained through the use of other monomers: trifluoroethyl (meth)acrylate; heptadecafluorodecyl (meth)acrylate; octafluoropentyl (meth)acrylate; eicosafluoroundecyl (meth)acrylate; hexadecafluorononyl (meth)acrylate; and tetrahydroperfluorodecyl (meth)acrylate.
  • Phosphorus-containing side chains for example the moieties which result from the polymerization of the monomers listed below and similar monomers.
  • Rz moieties and/or the functional groups thereon can also be obtained through the use of other monomers: 2-methacryloyloxyethyl phosphoryl choline; 2-acryloyloxypropyl phosphoryl choline; and stearyl fumaroylethyl phosphoryl choline.
  • Silicon-containing side chains for example the moieties which result from the polymerization of the groups of monomers and specific monomers listed below. It is noted that the identified Rz moieties and/or the functional groups thereon can also be obtained through the use of other monomers: silyl monomers, e.g.
  • Ligand groups which bind to target receptor sites. e.g., receptor proteins that are differentially over-expressed on target cells, for example cancerous cells. Ligands can be physically mixed as well as being part of the CYSC polymer. Ligands are discussed in detail later.
  • Some CYSC polymers include Z(Rz) moieties in which at least some of the Rz moieties are hydrophilic, the CYSC polymer then being an amphiphilic copolymer having both hydrophobic and hydrophilic characteristics. Formulations comprising such amphiphilic polymers may form micelles or emulsions or liposomes in water, for example containing a hydrophobic drug within the hydrophobic core. It is often convenient to provide CYSC polymers with hydrophilic character by the inclusion of polyoxyethylene oxide units (“pegylation”).
  • Some CYSC polymers include Z(Rz) moieties in which all the Rz moieties are hydrophobic, in which case the CYSC polymer will be a copolymer having only hydrophobic characteristics.
  • the CYSC polymer generally contains Z(Rz) moieties in amount less than 95%, particularly less than 70%, especially less than 100% or less than 50%, e.g. 5 to 25%, based on the weight of the polymer (e.g., 5, 7, 10, 15, 17, 20, 23 or 25%).
  • a CYSC polymer can be a homopolymer or copolymer which consists of Y(Rc) moieties.
  • many useful CYSC polymers contain less than 75%, or less than 50%, e.g. 1 to 75%, 5 to 50%, 15-50%, 15-30% or 10 to 25%, of Y(Rc) moieties, for example no more than 1%, 3%, 5%, 7%, 10%, 15%, 20%, 25%, 30%, 40% or 50% of Y(Rc) moieties.
  • the Rc moiety preferably contains at least 18 linear carbon atoms and/or the Y(Rc) moieties are present as grafted chains or blocks which consists essentially of the Y(Rc) moieties.
  • the backbone of a CYSC polymer can be of any kind.
  • the —Y— moieties, and the —Z— moieties if present, which can be the same as, or different from, the —Y— moieties can for example comprise carbon atoms which are linked to each other directly by covalent bonds or through other elements or combinations of elements, and repeating units can be linked to each other directly by covalent bonds or can contain linking units comprising one or more atoms e.g ester (including orthoester), amide, ether or phosphate linkages.
  • the CYSC polymer can be, or can comprise sections which are, polyacrylate, poly-alkyl acrylates, poly-fluoroacrylate, polymethacrylate, polyalkyl methacrylate, poly-N-alkyl methacrylamide, poly-alkyl oxazoline, poly-alkyl vinyl ether, poly-alkyl 1,2-epoxide, poly-alkyl glycidyl ether, poly-vinyl ester, poly-acrylamide, poly-methacrylamide, poly-maleimide, poly- ⁇ -olefin, poly-p-alkyl styrene, poly-alkyl vinyl ether, polyolefin, polyether, polyurethane, polysilane, polysiloxane, or poly(alkyl phosphazene).
  • the CYSC polymer can, for example, be derived from the addition and/or condensation polymerization of suitable monomers, e.g. acrylic, methacrylic, olefini
  • the melting temperature (Tp) of a CYSC polymer is primarily dependent on the number of carbon atoms directly linked to each other in a straight chain in the Cy moiety(s). Unlike most other crystalline polymers, whose crystallinity depends upon crystallization of the polymer backbone), CYSC polymers show relatively little change in melting temperature with changing molecular weight. Other things being equal, the greater the linear length of the Cy moiety, the higher the melting temperature. For example, the homopolymers of n-alkyl acrylates in which the n-alkyl group contains 14, 16, 18, 22, 30, 40 and 50 carbon atoms have melting temperatures of about 20, 36, 49, 60, 71, 76, 96 and 102° C. respectively.
  • the homopolymers of the corresponding n-alkyl methacrylates have melting temperatures of about 10, 26, 39, 50, 62, 68, 91 and 95° C. respectively.
  • the CYSC polymers used in this invention often have a melting temperature of 22 to 70° C., or 35 to 50° C., or 38 to 50° C., e.g. 37° C. to 42° C. or 40° C. to 47° C.
  • CYSC polymers with melting temperatures below 22° C., for example as low as 2° C., or higher than 70° C. may be useful in certain embodiments.
  • the melting temperatures of copolymers consisting of two or more Y(Rc) moieties reflects the relative proportions of the different Y(Rc) moieties.
  • the presence of Z(Rz) moieties generally reduces the melting temperature and broadens the melting range.
  • Random copolymers of the long linear chain n-alkyl acrylates and methacrylates generally have intermediate melting temperatures in the range of 0 to 85° C. dependent on the length of the n-alkyl chain Random copolymers with other monomers, e.g. acrylic acid or butyl acrylate, typically have somewhat lower melting temperatures.
  • Longer chain Z(Rz) comonomers exert greater influence on Tm depression than shorter chain Z(Rz) comonomers since the longer chain monomers have greater potential to disrupt the side chain crystalline domains.
  • CYSC polymers containing relatively small amounts of Cy moieties the extent of crystallinity can be enhanced by incorporating those moieties in blocks or grafts.
  • the heat of fusion of a polymer reflects the extent of its crystallinity. As a general rule, and other things being equal, the greater the proportion (if any) of Z(Rz) moieties, the lower the heat of fusion of a CYSC polymer. In a CYSC polymer containing particular proportions of particular Y(Rc) and Z(Rz) moieties, the heat of fusion will generally be greater if at least some of the Y(Rc) moieties are adjacent to each other.
  • a random copolymer containing Y(Rc) and Z(Rz) moieties will have less crystallinity (and therefore a lower heat of fusion) than (i) a block copolymer containing first blocks containing substantially all the Y(Rc) Moieties and second blocks containing substantially all the Z(Rz) moieties, or (ii) a graft copolymer in which the grafted chains consist essentially of all the Y(Rc) moieties.
  • the sharpness of the melting of the CYSC polymers can be quantified by reference to the value of Tp ⁇ To.
  • the CYSC polymer can have a Tp ⁇ To ⁇ Tp 0.7 , e.g. ⁇ Tp 0.6 . e.g. less than 15° C. or less than 10° C. or less than 5° C.
  • Tp ⁇ To can for example be less than 13.2, e.g. less than 9.1.
  • This narrow melting range can be very valuable particularly in combination with the ability to control molecular weight substantially independently of Tp, and the ability to select a CYSC polymer having a Tp close to in vivo temperatures. For example, it can facilitate mixing of a CYSC polymer with a drug at temperatures which do not degrade the drug.
  • the Tp of CYSC polymers is relatively little influenced by the molecular weight of the polymer. It is, therefore, possible, by selection of the repeating units of the polymer, to make CYSC polymers which melt at a desired temperature (e.g. from 2 to 105° C.) and over a relatively narrow temperature range, and which have a desired molecular weight.
  • CYSC polymers can be designed to have desired chemical and physical properties. As a result, CYSC polymers provide important benefits for loading and delivery of drugs and other drugs.
  • These benefits include for example the ability to make formulations at desired temperatures, in particular at temperatures which do not have any substantial adverse effect on the drug, and the ability to provide formulations having desired properties such as viscosity, adhesion, hydrophobicity, hydrophilicity, volume control, and permeability, loading and rate and/or pattern of release.
  • the CYSC polymers used in the invention do not have any crystallinity which results from crystallization of the polymer backbone (“main chain crystallinity”).
  • the CYSC polymer is a polymer obtained by modifying a main chain crystalline polymer to introduce Rc moieties at intermediate and/or terminal points on the polymer.
  • the CYSC polymer can for example be a random copolymer, graft copolymer or block copolymer (including a thermoplastic elastomer), or core-shell polymer.
  • Non-exclusive examples are as follows.
  • the polymer comprises one or more types of —Y(Rc)- moiety and one or more types of —Z(Rz)- moiety, all the moieties being randomly distributed.
  • the polymer is a block copolymer comprising (i) polymer blocks consisting essentially of one or more —Z(Rz)- moieties, and (ii) polymer blocks which comprise one or more types of repeating unit of the formula —Y(Rc)-, and optionally one or more types of repeating units of the formula —Z(Rz)-.
  • the polymer can be a graft polymer, for example (i) a polymer comprising a backbone which comprises, or consists essentially of, one or more —Y(Rc)- moieties, and grafted side chains each of which comprises, or consists essentially of, one or more —Z(Rz)- moieties, or (ii) a polymer comprising a backbone which comprises, or consists essentially of, one or more —Z(Rz)- moieties, and grafted side chains each of which comprises, or consists essentially of, one or more —Y(Rc)- moieties.
  • a graft polymer for example (i) a polymer comprising a backbone which comprises, or consists essentially of, one or more —Y(Rc)- moieties, and grafted side chains each of which comprises, or consists essentially of, one or more —Z(Rz)- moieties.
  • CYSC polymers which can be used in this invention include atactic, syndiotactic and isotactic polymers of n-alkyl ⁇ -olefins (e.g. the atactic and isotactic polymers of C16 olefin, having Tp's of 30° and 60° C. respectively); polymers of n-alkylglycidyl ethers (e.g. the polymer of C18 alkyl glycidylether); polymers of n-alkyl vinyl ethers (e.g. the polymer of C18 alkylvinylether having a Tp of 55° C.); polymers of n-alkyl- ⁇ -epoxides (e.g.
  • polymers of the polymer of the C18 alkyl ⁇ -epoxide having a Tp of 60° C. polymers of n-alkyl oxycarbonylamido-ethylmethacrylates (e.g. the polymers of C18 IEMA, C22 IEMA and C30 IEMA, having Tp's of 56° C., 75° C. and 79° C. respectively); polymers of n-fluoro alkyl acrylates (e.g. the polymer of C8 hexadecafluoroalkylacrylate and the polymer of a mixture of C8-12 alkyl fluoroacrylates, having Tp's of 74° C. and 88° C.
  • n-alkyl oxycarbonylamido-ethylmethacrylates e.g. the polymers of C18 IEMA, C22 IEMA and C30 IEMA, having Tp's of 56° C., 75° C. and 79° C. respectively
  • polymers of n-alkyloxazolines e.g. the polymer of C16 alkyl oxazoline having a Tp of 155° C.
  • polymers obtained by reacting an hydroxyalkyl acrylate or methacrylate with an alkyl isocyanate e.g. the polymers obtained by reacting hydroxyethyl acrylate with C18 or C22 alkyl isocyanate and having Tp's of 78° and 85° respectively
  • polymers obtained by reacting a difunctional isocyanate, a hydroxyalkyl acrylate or methacrylate, and a primary fatty alcohol e.g.
  • the Cy moieties in the CYSC polymers form crystalline aggregates by overlap of the Cy moieties with other Cy moieties in the same molecule or in a different molecule which may or may not be part of a CYSC polymer leading to intermolecular aggregates or domains of crystalline regions.
  • the molecular weight of the CYSC polymer can influence the incorporation and/or retention and/or delivery of a drug associated with the polymer.
  • the Mn of the CYSC polymer can for example be 500 to 1,000,000, e.g. 1,000 to 50,000, 2000 to 40,000, 2000 to 25,000, 2000 to 30,000, or 3000 to 20,000 daltons. In some cases it is preferred to use a CYSC polymer having an average molecular weight (Mn) of less than 200,000, or less than 100,000, or less than 50,000, or less than 30,000, or less than 25,000, or less than 20,000, or less than 10,000, or less than 5000, or less than 2500, or less than 1000 daltons, e.g.
  • CYSC polymers 1,000 to 20,000, all 1,000 to 10,000 or 2,000 to 20,000, or 3,000 to 5,000 daltons. In other cases, it may be appropriate to use CYSC polymers with a molecular weight greater than 1,000,000 daltons. It some cases, e.g., with a hydrogel, an infinite molecular weight is desired.
  • the molecular weight of the CYSC polymer moiety can be adjusted (for example through choice of the reaction conditions and addition of chain transfer agents), for example so as to optimize the reactivity of attached functional moieties without substantial change in Tp.
  • the ability to control the molecular weight of these polymers can assist in the mixing and processing of the formulations.
  • crosslinked gel and crosslinked solid CYSC polymers are desired, essentially, having an infinite molecular weight.
  • a gel which in its 100% form is a powder which can be mixed in the appropriate solvent with a drug to give the formulation.
  • transdermal applications it may be beneficial to have a low molecular weight.
  • the CYSC materials used for the administration of drugs to mammals should be nonabsorbable or essentially nonabsorbable in the patient's body. This is so both for implanted applications and ingested formulations.
  • the polymers as used by the invention are substantially physiologically inactive.
  • polymers which are of high molecular weight, e.g., Mn greater than 10,000 Daltons, charged or crosslinked polymers or polymers which are insoluble under physiological conditions eliminate or significantly reduce transportation of the polymer across a cell membrane or gut wall.
  • the CYSC polymers (or their break-down products have a molecular weight of below 20,000, or below 15,000 or more preferably below 10,000 Daltons and are not charged or crosslinked, and are thus voidable from the body.
  • solubility parameters of the polymer or various blocks or grafts within the copolymer can influence the solubility of a particular drug in the polymer, thereby, for example, improving the CYSC polymer's capacity and effectiveness as a drug reservoir.
  • solubility parameter estimations can be found in the book by D. W. Van Krevelan entitled “Properties of Polymers” Elsevier. 2003.
  • the partition coefficient, P, and pKa may be used to estimate distribution of drugs, particularly in biological applications.
  • the Log P and pKa assists in addressing CNS (central nervous system) penetration, oral absorption, intestinal absorption, colonic absorption, sub-lingual absorption, and percutaneous absorption, in addition to helping to optimise the physical form and composition of the drug formulation.
  • a pharmaceutical formulation which comprises a drug and a CYSC homopolymer or copolymer and which has one or more of the following characteristics:— (a) the formulation contains at least 5% or at least 10%, e.g. 5 to 30%, by weight of the drug; (b) the drug is associated with the polymer by one or more bonds selected from electrostatic bonds, hydrogen bonds, covalent bonds, or by entropic forces; B. A method of using a pharmaceutical formulation according to Statement A wherein the drug is released in a controlled manner. The method of Statement B optionally has one or more of the following characteristics.
  • the drug is released over an extended period of time; and (b) no more than 80%, preferably no more than 50%, for example no more than 30%, of the total drug loaded into the formulation is released from the formulation over a period of time of 6 hours following administration of the formulation to a subject; (c) less than 50%, or less than 10%, of the total drug loaded into the formulation is released over a period of time of 1 hour, or over a period of time of two hours, following administration of the formulation to a subject, (d) at least 75% of the total drug loaded into the formulation is released within 30 minutes of activation of the formulation; (e) the drug is released from the formulation by one or more of the following changes in condition
  • the formulation of the invention specifically excludes certain features, for example, in certain embodiments the polymer does not possess main chain crystallinity, or the polymer is not a block co-polymer and is not a graft co-polymer, or the polymer is not a hydrogel, or the polymer is hydrolytically stable, or the polymer is not an anhydride, or the polymer does not contain the structure Ra—CO—O—CO—Rb where Ra and Rb may be any moiety.
  • the CYSC polymers can be prepared in any way, for example using techniques which are well-known to those skilled in the art, e.g. emulsion, solution, bulk and suspension polymerization techniques using conventional catalysts.
  • Conventional additives and catalysts can be employed to achieve desired molecular weights, for example azo and peroxide catalysts, thiol chain transfer agents (e.g. alkyl mercaptans, hydroxyethyl mercaptan, butyl mercaptopropionate and mercapto acetic acid), or allyl chain transfer agents or regulators (e.g. including alpha-methyl styrene).
  • the type of polymerisation can often be selected according to the form of CYSC formulation to be administered.
  • emulsion polymerisation optionally in the presence of the drug
  • emulsion polymerisation optionally in the presence of the drug
  • a hydrogel form is preferred, polymerisation under aqueous or emulsion conditions can be employed; and if a spray-dried form is preferred, polymerisation under solvent conditions can be used.
  • Methods of preparing graft copolymers s include preparing a preformed polymer comprising Y(Rc) moieties and optionally Z(Rz) moieties, and then grafting suitable monomers (which may contain Rc and/or Rz moieties) at reactive sites at the end or in the middle of the preformed polymer.
  • Methods of preparing block copolymers include preparing two or more preformed polymers, at least one of the preformed polymers comprising Y(Rc) moieties and optionally Z(Rz) moieties, and at least one of the other preformed polymer(s) comprising Z(Rz) moieties, each of the preformed polymers having at least one reactive site at an end of, or between the ends of, the preformed polymer, and then reacting the preformed polymers to form the desired CYSC polymer.
  • a CYSC polymer may be prepared by copolymerising a vinyl type macromonomer with other monomers, or by making a CYSC polymer, and then reacting the functionalized polymer with the second block material, for example a urethane block, or an epoxy block, a polyether block, a polyester block, a polyethyleneoxide, polypropyleneoxide or polytetramethyleneoxide block, a polysiloxane block, or a poly(alkyl or alkoxy)silane block.
  • the second block material for example a urethane block, or an epoxy block, a polyether block, a polyester block, a polyethyleneoxide, polypropyleneoxide or polytetramethyleneoxide block, a polysiloxane block, or a poly(alkyl or alkoxy)silane block.
  • the CYSC polymers used in the formulations of the invention are specifically not cross-linked. In certain embodiments, such as hydrogel formulations, however, they may be cross-linked.
  • the monomer starting material can include a cross-linking monomer, for example to control crosslink density in a hydrogel.
  • Crosslinking monomers or crosslinking reactants can be added at various times during the process including (a) when preparing the polymer in a desired shape followed later by the addition of therapeutic drug or (b) after separately preparing polymer, combining such polymer with therapeutic drug and then finally adding a crosslinking agent to set into a particular shape.
  • a single CYSC polymer or a mixture of CYSC polymers can be used.
  • the CYSC polymer or polymers can also be mixed with an additional polymer which is not a CYSC polymer.
  • the criteria for the selection of a particular CYSC polymer or mixture of CYSC polymers, and optionally one or more additional polymers, depend upon the drug and its desired loading and/or delivery, as further discussed herein.
  • Some embodiments of the invention make use of a composition containing a mixture of two or more CYSC polymers having substantially different melting temperatures, for example melting temperatures which differ from each other by at least 2° C., or at least 4° C. or at least 6° C. or at least 8° C. or at least 10° C.
  • the composition may contain one or more polymers melting at 37° C. and others melting at 39° C. and still others melting at 41° C.
  • Other embodiments make use of mixtures of polymers having drug bound through a range of ionic strengths as defined by the pKa or pKb of the drug-polymer pair.
  • the amount of the drug is at least 5%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 55%, at least 60%, or at least 70% of the total weight of the composition.
  • Some formulations may have between 0.1% and 5%, for example up to 2%, 3% or 4% drug.
  • One of the many useful characteristics of this invention is the possibility of matching a particular drug with a particular CYSC polymer or mixture of CYSC polymers so as to provide desired loading and release characteristics.
  • a CYSC polymer which contains containing hydrophobic side chains and optionally hydrophilic moieties provided by Rz moieties, and which therefore interacts favorably with the drug.
  • the CYSC polymer can provide sites for association with a drug by van der Waal's forces, ionic association, hydrogen bonding, ligand attachment or covalent bonding. Covalent bonds may be formed for example through an amino or carboxyl linkage, or a divalent organic or inorganic moiety, e.g.
  • Ionic bonds may be formed for example through an ionic salt linkage (for example a carboxyalkyl ammonium, sulfonium or phosphonium ion pair).
  • the CYSC polymer may comprise an amphiphilic structure, with both hydrophobic and hydrophilic moieties, entropic considerations will tend to produce a secondary structure wherein the hydrophilic moieties position themselves on the outside of the structure in an aqueous environment and wherein hydrophobic drug molecules are retained within the interior hydrophobic environment.
  • Drugs may be hydrophobic or hydrophilic and may associate with the hydrophobic or hydrophilic moieties of the polymer.
  • a CYSC polymer comprises hydrophobic side chain moieties, and as a result a hydrophobic drug may associate with the hydrophobic moieties and thus be protected from an aqueous environment surrounding the formulation.
  • Hydrophobic drugs include, for example, statins, such as atorvastatin, symvastin and pravastatin, SSRIs such as sertraline, anti-inflammatory-steroid such as budesonide, risperidone and many other pharmaceutically important molecules.
  • the CYSC polymer includes units comprising ionic groups, e.g. units derived from ionic vinyl monomers.
  • the ionic groups can help to stabilize the polymer formulation or help in disassociating the formulation in body fluids.
  • a CYSC polymer containing carboxylate functional groups can reduce or eliminate release of a drug in the acidic environment of the stomach, but can swell in the alkaline environment of the small intestine, thereby releasing the drug in the upper intestine.
  • PEGylated monomers or acidic or other non-ionic or ionic monomers respectively may be incorporated together as part of the same CYSC polymer or may be present in separate CYSC polymers to be mixed with a drug.
  • the route of drug administration will often be a factor in determining the desirability of the number of ionic or hydrogen bonding groups in the CYSC polymer.
  • a small protein or polypeptide can be mixed with a CYSC polymer to make a stable drug formulation and then administered orally.
  • the protein administered by itself orally might be destroyed when exposed to the high acidic environment of the stomach.
  • the protein When mixed with CYSC polymer, the protein would be protected from degradation.
  • an acid-stable component may be added such as transferrin.
  • a protein may be complexed with an absorption enhancing component such as an organic acid, for example with deoxycholic acid, hydroxypropyl-g-cyclodextrin, cholic acid.
  • the Z(Rz)- moieties may also enhance the physical surface properties of the formulation.
  • polyoxyethylene (meth)acrylate units can provide beneficial slip or hydrophilic properties to tubing, catheters, probes and other medical devices.
  • the Z(Rz) moieties may also help in the sustained release or delivery of the drug.
  • burst it is often desirable to reduce burst in order to provide a more steady or zero order delivery of drug to an mammal or cell.
  • burst it is often observed in drug delivery formulations that upon administration there is an initial release of drug from the formulation above the desired therapeutic level, thereby, wasting and often overdosing the drug and in turn reducing the long term theoretical release of drug in the formulation to the mammal or cell.
  • the CYSC polymer and drug formulation can be treated with solvents, buffered solutions or other aqueous or aqueous and organic solvent solutions for periods of time at ambient conditions. After this treatment the resulting CYSC polymer and drug formulation generally will exhibit a much lower and in some cases almost no burst effect.
  • This embodiment is a significant advantage of preferred CYSC polymers of this invention compared to other drug delivery polymers.
  • the presence of PEGylated groupings in the CYSC polymer can increase serum half-life levels of the PEGylated drug, and can reduce immunogenicity and immune recognition of the PEGylated drug.
  • Other enhanced properties that may be provided by PEGylation include bioadhesive properties, and antithrombogenic properties.
  • the Z(Rz) moiety can assist in making the polymer formulation more bioadhesive.
  • carboxylic acid or hydroxyl moieties can improve bioadhesivity to muco or intestinal surfaces, as can heparin and heparin sulphates.
  • Hydroxyl or alkoxy polyoxyethlene moieties can also assist in bioadhesion and compatability of the drug.
  • the CYSC polymer contains moieties which, either by hydrogen bonding or ionic bonding or covalent bonding, associate with the drug. These moieties may be derived from comonomers which constitute a minor proportion of the monomers from which the CYSC polymer is derived, for example 1% to 50% by weight (e.g., less than 1, 3, 5, 7, 10, 15, 20, 25, 30, 35 or 40% or from 1-5%, from 1-10%, or from 1-20%), or a major proportion, for example 50 to 95% or 75 to 95% by weight, or any weight in between, of the CYSC polymer (e.g., more than 30, 40, 50, 60, 70, 80, 85, 90 or 95% or from 20-40%, from 30-50%, or from 50-80%).
  • moieties may be derived from comonomers which constitute a minor proportion of the monomers from which the CYSC polymer is derived, for example 1% to 50% by weight (e.g., less than 1, 3, 5, 7, 10, 15, 20, 25, 30, 35 or 40%
  • the selection and amount of the comonomers providing hydrogen bonding or ionic bonding is preferably based on:
  • the CYSC polymer includes Z(Rz) moieties that can form a covalent bond with the drug.
  • the extent of covalent linkage between the CYSC polymer and the drug will be an important factor in determining release characteristics of the formulation.
  • a copolymerizable monomer is used to bind the drug covalently to assist in the eventual release of the drug from the polymer formulation.
  • Various covalent bonds may be used to bind the drug to the polymer; some may acid labile, some base labile, and some sensitive to enzymatic cleavage.
  • any method can be used to covalently bind a drug to a CYSC polymer.
  • the CYSC polymer contains a reactive group which is reacted with the drug.
  • the drug is modified so that it can be used as a comonomer in the preparation of the CYSC material.
  • the drug can be reacted with a vinyl-containing monomer, e.g.
  • the modified drug is copolymerized with one or more other monomers, at least one of which comprises a Cy moiety, or with an oligomer or macromer containing a Cy moiety, to give a CYSC formulation.
  • the formulation is such that a covalently bound drug is released from the CYSC polymer under conditions of low pH or by gastric enzymes.
  • active ingredients are those medicinal agents wherein gastric release is preferred over intestinal release or wherein control of the rate of release of the active agent is desired for systemic action.
  • drugs in which delivery to the stomach is preferred include natural or synthetic prostaglandins and prostaglandin analogues and prostacyclins, (e.g., misoprostol, enisoprost, enprostil, iloprost, and arbaprostil) any drugs for the treatment of peptic ulcers, gastric antisecretory drugs, antimicrobial drugs, prokinetic drugs, cytoprotective drugs and the like.
  • antimicrobial drugs include tetracycline, metronidazole and erythromycin which can be used for eradication of gastric microbes such as Heliobacter pylori.
  • drugs are bonded to a CYSC polymer for release in an acidic environment depending on the desired physiological action of the drug, systemic side effects associated with each drug, decomposition rate of the drug in a particular environment and other factors well known in the medicinal arts.
  • a covalent bond may be pH sensitive and capable of being cleaved at pH values of up to about 7 but stable below that pH.
  • Covalent bonds which can be cleaved under acidic conditions include bonds of the following types: silyl ethers and esters, acetal, thioacetal, imines, amine, carbonates, and vinyl ethers.
  • Silyl ether covalent bonds are preferred in certain embodiments because such a bond can be formed between a silyl functional group on the polymer (or linker group) and any hydroxyl functional groups on the drug.
  • the drug can be covalently bonded to the polymer backbone or to a pendant functional group on the polymer backbone and can for example be released from the polymer by hydrolytic cleavage of the covalent bond at a pH below about 7.
  • the drug can be incorporated into the polymer by way of a pH-sensitive covalent bond which can for example be cleaved at pH values of less than about 7 but not at higher pH values. Release of the drug at such higher pH values, such as about greater than 7, 8, 9 or 10 or higher, is inhibited.
  • the CYSC polymer swells at desired pH values, for example pH values of about 1-7 to enhance release of an effective amount of the drug.
  • the drug can for example be covalently bonded to the polymer as described above through a pH-sensitive linker such that when the polymer swells upon exposure to the acid environment, the release of the drug into the gastric environment is facilitated.
  • the formulation releases the drug at pH values up to about 7 and inhibits release of the drug for inhibiting release of the active ingredient at pH values above 7.
  • the polymer can be designed such that the drug remains attached to the polymer at low pH and is triggered to release at high pH.
  • ibuprofen p-i-butylphenyl propionic acid
  • the modified drug is copolymerised with a linear alkyl acrylate (stearyl acrylate) and an additional copolymerizable monomer, acrylic acid, to give an Ibuprofen CYSC acid containing drug formulation.
  • This drug formulation administered as a crystalline solid, would bypass the stomach and once in the upper intestine would hydrate, swell, and hydrolyze, releasing ibuprofen for colonic delivery of this drug.
  • ibuprofen can be esterified with a preformed crystalline copolymer of stearyl acrylate and hydroxyethyl (meth)acrylate.
  • ibuprofen acid containing CYSC formulation would be available for colonic delivery of ibuprofen.
  • acryloyl chloride is reacted with a hydroxyl group or an amine group of a drug to provide a vinyl containing attachment covalently linked to the drug.
  • This drug-vinyl monomer can then be reacted with the side chain crystalline monomer.
  • a vinyl anhydride e.g. methacrylic anhydride
  • a hydroxyl-containing drug is reacted with a hydroxyl-containing drug to form a covalent ester linkage between the vinyl anhydride and the drug.
  • side chain crystalline monomer is introduced into the reaction mixture and a copolymer is formed between the modified drug, the side chain crystalline monomer and the by-product methacrylic acid (formed from the reaction of the hydroxyl containing drug with the vinyl anhydride).
  • the reaction by-product of methacrylic acid in this case is easier to handle than the hydrochloric acid by-product obtained with the reaction of acryoyl chloride in the earlier example.
  • the methacrylic acid by-product becomes a comonomer with the vinyl group containing therapeutic drug molecule.
  • This type of formulation would be useful for an orally administered drug that, if administered alone, would be damaging to the stomach.
  • the presence of excess copolymerized methacrylic acid would help hydrate the molecule once the formulation has passed through the stomach to the small intestine for hydrolysis of the covalent bound drug and absorption in the small intestine.
  • a PLGA polymer can be functionalized with a drug like Ibuprofen (p-i-butylphenyl propionic acid) through reaction of the carboxylic acid group of Ibuprofen with the OH terminal group of PLGA.
  • this material can be succinylated with succinic anhydride and the remaining carboxylic acid group can be esterified with a polyol, for example, glycerine, and then end capped with stearic acid or stearoyl chloride to make a bioerodible CYSC polymer covalently bonded to a drug, in this example, Ibuprofen.
  • a polyol for example, glycerine
  • a PLGA can be esterified at the terminal hydroxyl group to create a PLGA stearate which can be reacted with polyol, for example glycerine and then esterified with Ibuprofen to give another form of a bioerodible CYSC polymer covalently bonded to a drug, in this case again, Ibuprofen.
  • polyol for example glycerine
  • Ibuprofen esterified with Ibuprofen to give another form of a bioerodible CYSC polymer covalently bonded to a drug, in this case again, Ibuprofen.
  • a covalently bound drug is released from the polymer carrier enzymatically, for example through ester hydrolysis by an esterase enzyme that would hydrolyze all the acrylate ester linkages.
  • the CYSC polymer comprises functional groups to assist in the transport of the formulation into a biological system e.g., through a membrane or into a cell or through a mucous membrane layer, or to assist in the adherence of the formulation to deliver the drug.
  • the formulation can include mucoadhesives sites, dermal adhesives, or large molecules that enhance bioavailability and reduce immunogenicity, for example, polyoxyalkylene vinyl monomers may be linked to PEG or PEGylated groups. These PEGylated groupings in the CYSC polymer will typically be introduced as comonomers, [Z(Rz)].
  • the formulation includes a ligand to provide targeted adherence of the formulation to a target receptor on the target tissue.
  • Ligand molecules can be added to the formulation during or after formation of the drug-polymer formulation.
  • a complexing molecule, a ketoester or a diamine containing copolymerizable monomer may be incorporated by polymerisation into the CYSC polymer. This complexing group can interact with a ligand as the formulation is prepared.
  • drug-polymer formulations can be manufactured and then targeted to the desired target tissue, for example after biopsy and tissue analysis.
  • the CYSC polymer provides a number of interacting ionic and hydrogen bonding groups that assist in sterically protecting the sensitive drug in the harsh acidic environment of the stomach.
  • the crystalline side chains will lock the protein or peptide in the hydrophobic side chains, thereby, providing steric protection to the acid sensitive drug.
  • the higher pH upper intestine will hydrate the ionic groups of the CYSC polymer allowing release of the sensitive drug into the intestinal tract.
  • the polymer may release or expose the drug by various means including swelling, hydrolysis and by melting by external thermal induction, or by any combination of these means.
  • a CYSC polymer derived from a linear alkyl acrylate monomer and an acid-containing monomer can be mixed with an amine containing drug, e.g., Sertraline, and cooled to provide a formulation.
  • an amine containing drug e.g., Sertraline
  • the polymer drug ionic structure crystallizes. Once ingested, the crystalline domains protect the drug from reaction with components of body fluids. In its crystalline form this drug is protected from the acidic stomach environment and would not be available for absorption, whereas in the upper intestine the CYSC polymer would hydrate with the excess of acid groups in the CYSC polymer, thereby, releasing the Sertraline for absorption in the upper intestine.
  • the CYSC polymer is in the form of a hydrogel.
  • the invention specifically excludes a hydrogel.
  • Hydrogels are preferred in some cases because a solid powdered hydrogel can be easily mixed with a solid powdered drug and then hydrated for application. Hydrogels can be hydrophobic, or amphiphilic (i.e. hydrophobic and hydrophilic), and they can be ionic or non-ionic.
  • a CYSC polymer containing units derived from a N-iso-propyl acrylamide comonomer, either alone or in combination with units derived from acrylic and, or methacrylic acid can form hydrogels which are both hydrophobic (from the side chain crystalline monomers) and hydrophilic (from the N-iso-propyl acrylamide and acrylic acid monomers) and which can associate with (depending on the percentage of the hydrophobic and hydrophilic portions) either a hydrophobic or a hydrophilic drug.
  • Non-ionic hydrogels swell when they absorb water.
  • Ionic hydrogels which can be anionic or cationic, can be caused to swell to varying degrees by a change in pH.
  • An alkaline pH causes swelling of an anionic gel (because an ionic groups are ionized at high pH), whereas a low pH causes swelling of cationic gels.
  • the drug is hydrophilic
  • the drug is absorbed in the hydrophilic portion of the amphiphilic CYSC polymer hydrogel.
  • the hydrogel can be designed to swell at high pH or low pH and/or at a temperature above the melting temperature of the CYSC polymer when mixed with the drug. After cooling, the drug is captured in the CYSC polymer hydrogel. If the formulation is heated after it has been delivered, it releases the drug.
  • the temperature switch of the hydrophobic side chain portion, the hydrophobic property of the side chains and the hydrogel properties are factors which influence the delivery of the drug.
  • the CYSC polymer is in the form of a non-ionic hydrogel prepared by polymerizing monomer component comprising an SCC monomer and a neutral hydrophilic comonomer, for example, hydroxyethyl methacrylate, together with a small portion of a crosslinking agent, e.g. ethylene glycol dimethacrylate.
  • a crosslinking agent e.g. ethylene glycol dimethacrylate
  • polyoxyethlene glycol methacrylate monomer may also be included, thus adding to the gel structure and providing possible antithrombogenic properties to the formulation.
  • This polymer is also an amphiphilic polymer. As such it can be compatible with either or both hydrophilic or hydrophobic drugs.
  • the amount and type of side chain crystalline monomer and the hydrogel structure can be factors in regulating how the drug in the formulation is released, e.g. how fast, where, and when, particularly if external stimuli to change temperature are provided.
  • the formulation comprises a neutral hydrogel prepared by polymerizing an SCC monomer, acrylamide and t-butyl acrylamide, together with a small amount of methylene bis acrylamide.
  • a hydrogel can associate with a hydrophilic or hydrophobic drug.
  • the formulation comprises a hydrogel prepared by polymerizing an SCC monomer, acrylic acid and a block polyoxypropylene/polyoxyethylene/polyoxypropylene ester of acrylic or methacrylic acid.
  • the resulting amphiphilic CYSC polymer dependent on the block structure of the oxyalkylene ester, will absorb varying amounts of a hydrophilic or a hydrophobic drug or a little of both drugs. These drugs may be released slowly dependent on the hydrophobe/hydrophile balance of the oxyalkylene ester and the hydrophobe from the SCC monomer.
  • the units derived from the SCC monomer provide a powerful tool for regulating the uptake into, and the later delivery of a drug from, a formulation of this invention.
  • the gel or hydrogel structure can help to regulate the release of drug to the location desired.
  • a pH sensitive hydrogel containing units derived from acrylic acid will facilitate protein loading.
  • Formulations of protein and acid hydrogel protect the protein in the stomach, but swell and release the low pH sensitive protein in the small intestine, where the alkaline environment causes hydration and swelling of the hydrogel by interaction with the units derived from, for example, copolymerised acrylic acid.
  • the swelling of the hydrogel can regulate the release of drug, because the hydrogel acts like a membrane, thereby overcoming the normal “burst effect” and allowing slow but deliberate release of the protein.
  • the formulation contains a crosslinked CYSC polymer which, because it at least partially retains its shape even under conditions which would cause melting or swelling of the corresponding non-cross-linked CYSC polymer, e.g. above its Tp, will tend to hold a drug longer than the corresponding non-crosslinked polymer.
  • Other embodiments specifically exclude CYSC polymers which are cross linked or immobilized on a support so that they cannot flow at temperatures above their melting temperature.
  • the molecular weight of the CYSC polymer is preferably high enough to limit or avoid absorption across the intestinal wall.
  • polymers which are of high molecular weight, e.g., 1,000-160,000 Mn, and/or which are charged or crosslinked, and/or which are insoluble under physiological conditions eliminate or significantly reduce transportation of the polymer across the gut wall.
  • the CYSC polymer carrier after having released the drug, will be passed through the GI tract and be voided.
  • the CYSC polymer be substantially physiologically inactive.
  • the formulation includes or is secured to a bioerodable polymer, e.g. PLA or PLGA.
  • a bioerodable polymer e.g. PLA or PLGA.
  • Implanted applications may employ a mechanically solid implant wherein the CYSC formulation is bound to or contained within the bioerodable polymer.
  • the formulation is delivered intravenously.
  • polylactic acid and/or polyglycolic acid can be grafted by covalent reaction to the CYSC polymer before it is associated with the drug.
  • a highly crystalline bioerodable polymer e.g. a polycaprolactone polymer, e.g. of a desired molecular weight, which will provide a straight chain crystalline moiety, is physically mixed with, the CYSC polymer before it is associated with the drug.
  • the CYSC polymer has a gel structure provided by the inclusion in the monomer mixture of a cross-linking multifunctional monomer.
  • a cross-linking multifunctional monomer Such monomers are best employed in emulsion polymerizations, since, in other types of polymerization, they result in viscosities which are difficult to handle.
  • Exemplary crosslinking monomers are ethylene glycol dimethacrylate, butylene glycol dimethacrylate, trimethylol propane triacrylate hexane diol diacrylate and the like. These crosslinking monomers are generally employed only in small amounts, e.g. less than 0.5%, or less than 1%, such as 0.1% to 5%, or 0.2 to 2%.
  • the formulations of the invention can contain, or be coated with, or be coated onto, any other material which does not have a substantial adverse effect on the value of the formulation as a drug delivery vehicle. Many such materials are well-known to those of ordinary skill in the art.
  • the formulation includes additives commonly used in the pharmaceutical industry, e.g. for the manufacture of tablets, pills or capsules, including excipients such as binding agents (e.g. methyl cellulose); fillers (e.g. corn starch, sucrose); lubricants (e.g. stearic acid, magnesium stearate, colloidal silica); and disintegrators (e.g. sodium starch glycolate, alginic acid.
  • Formulations in the form of particles or tablets can have coatings thereon, e.g. coatings of materials such as hydroxypropyl methyl cellulose and acrylic acid polymers and copolymers. Certain embodiments specifically exclude formulations containing components which are useful as herbicides and insecticides.
  • the CYSC polymer is in the form of an emulsion.
  • the average size of the particles in the emulsion (and preferably the maximum size of substantially all particles) is preferably less than 1200 nm, e.g. less than 800 nm or less than 500 nm, for example less than 200 nm or less than 100 nm (0.1 ⁇ ).
  • the size of emulsion particles is 50-200 nm, or 50-500 nm, or 100-1000 nm.
  • Such emulsions can be prepared using the techniques described in U.S. Pat. Nos. 6,199,318 and 6,540,984, the entire disclosures of which are incorporated herein by reference for all purposes.
  • Emulsions are for example useful for compositions to be injected, generally intravenously, but in some embodiments, intramuscularly or into other tissues. In general, injectable emulsion particles have a diameter of less than 800 nm.
  • Emulsion polymers may be made prior to mixing with a drug and in other cases in the presence of a drug.
  • emulsions of particles containing a drug immobilized within a CYSC polymer can be formed by a number of routes including (a) emulsifying a mixture of polymer and drug in water using a variety of surfactants and emulsifiers, (b) emulsifying a polymer-drug conjugate (with polymer-drug conjugate being defined as the drug being chemically bound to the polymer through covalent, ionic or hydrogen bonding) in water using a variety of surfactants and emulsifiers, (c) pre-emulsifying a preformed polymer and then adding a therapeutic drug that has a preferred partition coefficient such that the drug prefers to enter the hydrophobic particle and is either un-bound or linked through a covalent, ionic or hydrogen and, (d) preparing a stable water based polymer by emulsion polymerization and then adding drug as
  • the formulation comprises not only a CYSC polymer but also another type of polymer, which may be a main-chain crystalline polymer.
  • the CYSC polymer can be mixed with an amorphous or main-chain crystalline lactide or mixture of glycolide and lactide crystalline main-chain PLGA polymer, or with poly(epsilon-caprolactone (PCL), poly(dioxanone—a polyether-ester), polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV) and polyhydroxyalkanoates (PHAs), and polyesters from 3-HP—3-hydroxypropionic acid.
  • PCL poly(epsilon-caprolactone
  • PDB poly(dioxanone—a polyether-ester)
  • PHB polyhydroxybutyrate
  • PV polyhydroxyvalerate
  • PHAs polyhydroxyalkanoates
  • a diluent in the formulation naturally occurring polymers or their hydrolysis or degraded products such as sugars, hydrolyzed starches, hyaluronan (also called hyaluronic acid or hyaluronate), chitan or chitosan may be used.
  • hyaluronan also called hyaluronic acid or hyaluronate
  • chitan or chitosan may be used as a diluent in the formulation.
  • the formulation is prepared by melting the CYSC polymer, mixing the drug with the molten polymer, and cooling the mixture to below its melting point to cause crystallization and solidification of the formulation.
  • a solvent may be used to help the drug and the polymer mix, but in other embodiments no solvent is required due to the low melting point of the CYSC polymers used.
  • Carriers, fillers, excipients, dyes, colorings, flavors, distinegrants, stabilizers and other materials may be added to the mixture before it solidifies.
  • the formulation can be processed, either while the polymer is still molten or object has solidified for example into rods, ovals, other forms, and tablets etc using known procedures.
  • the CYSC polymer can be selected to have a Tp and a melting range such that there is little or no danger that the drug will be exposed to a temperature or pH which will damage it.
  • Some CYCS polymers have well defined, low melting temperatures such that it is unnecessary to use solvent to achieve the viscosity needed to allow easy mixing.
  • the invention is particularly useful for the formulation of drugs and other drugs which can be damaged, e.g. denatured or partially or completely inactivated, by such exposure, for example drugs which are damaged by exposure to temperatures higher than a temperature which is more than 15° C., or more than 30° C. above the Tp of the CYSC polymer, for example more than 50° C. or more than 65° C.
  • the melting temperature of the polymer (or polymer mixture) used in the formulation may, for example, be about (or alternatively be not more than) 30° C., about 35° C., about 37° C., about 40° C., about 42° C., about 45° C., about 50° C., about 55° C., about 60° C., about 65° C., about 70° C., about 75° C., about 80° C., or other temperature desired.
  • the polymers may, for example, have melting temperature ranges from 35° C. to 65° C., 40° C. to 65° C., 45° C. to 60° C., 40° C. to 60° C., 50° C. to 65° C., or other range between or within any two of the above temperatures.
  • a polymer-drug composition will have a melting temperature above that of body temperature of the subject (e.g., 37° C.). However, in some embodiments, it will be desirable that the polymer-drug composition have a melting temperature above 37° C., so that the dosage form, once implanted maintains a non-solid consistency.
  • the mixture of the drug and melted polymer is dispersed rapidly into cold water or spray dried into a chamber, whereby the polymer formulation precipitates or dries, respectively, into an isolatable form.
  • Microspheres and microcapsules may be formed in this way.
  • the drug formulations of the invention particularly exclude microspheres and microcapsules.
  • this invention provides one or more of high drug loading, low burst effect, and sustained release of a drug from a CYSC polymer formulation tailored to provide the desired characteristics for the particular drug.
  • Total drug loading is the amount (usually expressed as the percentage by weight) of the drug present in the formulation.
  • the drug may be chemically and/or physically bound to the CYSC polymer, for example physically entrapped in the formulation. Binding of the drug to the polymer may be through covalent and/or ionic and/or hydrogen bonding and/or van der Waal's forces and/or hydrophobic interactions.
  • the formulation of this invention contains at least 1% by weight of the drug.
  • the formulation can contain at least 1%, at least 2%, at least 5%, at least 7%, at least 10%, at least 15%, at least 17%, at least 20%, at least 30%, at least 40%, at least 45% at least 50%, at least 60%, or at least 70%, e.g.
  • the formulation contains at least 10% by weight of drug, and generally between 10% and 30% by weight of drug. In other embodiments, the formulation can contain less than 1% of the drug. High drug loading is particularly useful for sustained release formulations. In some embodiments, the present invention combines high drug loading with reduced burst effect.
  • Tailoring drug loading and release properties for a particular drug may be achieved for example through selecting polymers with a combination of desired features relating to (a) ionic or covalent attachment of drug molecules to CYSC polymer, and/or (b) capturing the drug molecules in the crystalline hydrophobic domain, and/or (c) presenting a tortuous path around crystalline domains that drug molecules in the hydrophilic domains must navigate to reach the exterior and/or (d) ensuring that the crystalline domains are preferentially on the outside of the formulation.
  • Methods of preferentially locating the crystalline domains on the exterior include, for example, forming particles in air using a spinning disk allowing the hydrophobic side chains to come to the low energy interface or in a hydrophobic medium that would again draw the hydrophobic side chain to the interface, or actually coating preformed particles.
  • Drug loading and release properties of CYSC polymer formulations can be controlled by altering the solubility of the drug in the polymer and providing association sites for the drug to interact with the CYSC polymer.
  • the ionic groups in the CYSC polymer are preferably selected from those cationic or anionic groups which naturally associate ionically or through hydrogen bonding with the carboxyl or amide groups of the protein or polypeptide side chains.
  • Such ionic groups can be derived from suitable cationic or anionic comonomers forming part of the CYSC polymer or can be subsequently prepared on the preformed polymer by quaternization of, for example, a tertiary amine comonomer copolymerized in the crystalline side chain polymer. Quaternization of a tertiary amine function on the crystalline side chain copolymer can be affected by methyl or some other alkyl chloride or by dimethyl or other dialkyl sulfate treatment of the t-amine to form the quaternary ammonium salt.
  • a more hydrophobic drug may have a lower concentration of a hydrogen bondable or ionic group containing monomers. Yet, there are many hydrophobic monomers that contain ionic groups or contain hydrogen bonding capability to allow the more hydrophobic drug molecules to form strong ionic or hydrogen bonded associations with a therapeutic molecule.
  • a formulation of the invention (such as an implanted drug formulation or device, such as a coated stent or solid implant or polymeric drug depot) may provide at least 5 hours, at least 12 hours, at least 24 hours, at least 36 hours, at least 72 hours or at least 100 hours of therapeutically effective drug delivery.
  • a formulation of the invention may provide at least a week or at least two weeks, three weeks or at least a month or three month's worth of therapeutically effective drug delivery to a subject.
  • interactions between the drug and the CYSC polymer slow the release of the drug from the polymer into the surrounding physiological environment.
  • the interaction of the hydrophobic side chains of the crystalline side chain polymer with a hydrophobic drug will delay dissociation of the CYSC polymer and drug.
  • the drug is hydrophilic, the drug will tend to associate strongly with the hydrophobic side chains of the CYSC polymer, delaying release into a less hydrophobic (e.g. aqueous) environment.
  • the side chains of the CYSC polymer influence melt temperature and once melted act somewhat like a plasticizer (i.e. an attached plasticizer).
  • the molecular weight of the polymer also influences the release of the drug (for example molecular weight influences in drug diffusion from a crosslinked gel vs. a low molecular weight polymer). These factors are important in controlling the release rate of drug from the polymer drug formulation. If the CYSC polymer associates with the drug by ionic or hydrogen bonding, the drug will be slower to release.
  • the drug formulations of the invention can be specifically designed to provide controlled and/or sustained release.
  • a drug formulation of the invention may be designed so as to release no more than a certain amount of drug over a specific period of time under certain defined circumstances.
  • the rate of loading and release will depend on the specific drug-polymer pair.
  • a single dose of a drug formulation may release no more than 5% of the total drug loaded into the dosage form, or alternatively no more than 1%, 3%, 10%, 20%, 30%, 40%, 50%, 60% or 70% over a period of 1 hour, or alternatively 3 hours, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours or any combination of the foregoing numbers.
  • the rate of drug released may be approximately zero order during the main period of therapeutic administration, for example over 99% or 95% or 90% or 80% or 75% of the period of therapeutic administration, or over a period defined by the period of implantation.
  • the maximal variation of drug release rate over the main period of therapeutic administration (for example during the period when therapeutic administration is occurring, at least 12 hours following administration, and before drug release falls below a therapeutically effective level) may not be greater than 50% (or 40% or 30% or 20% or 10%) from the mean rate of release during that period.
  • the plasma concentration of a drug will be related to the rate of release into the blood balanced against the rate of clearing of the drug from the blood (the drug half-life concentration).
  • the aim of sustained drug delivery is to achieve a therapeutic plasma concentration of the drug over a desirable extended period of time.
  • the desired therapeutic plasma concentration will be a concentration within the therapeutic window below which drug is ineffective, and above which the drug is toxic, or alternatively has no additional beneficial effect.
  • a therapeutic dose of the drug as measured by plasma concentration will be released over a period of time ranging from at least an hour to at least twelve months.
  • exemplary drugs suitable for sustained release include, for example, anti-pain medications (e.g. morphine analogues), anti-psychotics (e.g. risperidone), anti-inflammatories (e.g. steroids or NSAIDs), cholesterol lowering drugs (e.g., statins), osteoporosis drugs (biphosphonates), anti-angeogenics (e.g., anti-VEGF) and contraceptives.
  • anti-pain medications e.g. morphine analogues
  • anti-psychotics e.g. risperidone
  • anti-inflammatories e.g. steroids or NSAIDs
  • cholesterol lowering drugs e.g., statins
  • osteoporosis drugs biphosphonates
  • anti-angeogenics e.g., anti-VEGF
  • sustained release may be desirable over a period of more than a year, for example at least 2, 3, 4, or 5 years.
  • Prior formulations Plant
  • Prior formulations have been used to deliver a therapeutic dose of contraceptives over a period of three years.
  • Long term sustained release formulations will generally be formulated for implantation within the body, e.g., subcutaneously.
  • the amount (weight) of drug released over a period of time will of course be related to therapeutically effective plasma concentration of the drug, the potency of the drug and drug kinetics including the residence time in the various tissues of interest and the rate of clearing.
  • the rate of release of a drug from the pharmaceutical composition of the invention may be no greater than, for example 10 ng per hour, or alternatively, 50 ng, 100 ng, 500 ng, 1000 ng, 2500 ng, or 5000 ng or in other embodiments, no more than 10 ⁇ g, 50 ⁇ g or 100 ⁇ g or 500 ⁇ g or 1000 ⁇ g per hour during the first 6 (or 12 or 24 or 36) hours following implantation.
  • Risperidone may be released over a period of time to provide a serum concentration of about 15 ng/ml up to about 100 ng/ml. A release of about 4 mg/day (or in other studies between 1 and 60 mg/day) is found to provide adequate therapeutic serum levels of Risperidone.
  • the drug when the drug is released from the formulation, it is released into the surrounding environment, which may be, for example, the intestinal lumen, gastric fluid, subcutaneous tissue, blood, muscle, the colonic space, a body cavity, or any surrounding tissue and/or into interstitial space.
  • the rate of the release is not always easy to measure in practice, and the invention includes methods of determining the rate of release of a drug from a formulation of the invention in vitro, such as by using standard methods such as those described in the United States Pharmacopoeia.
  • One such method employs a large volume (usually about a litre) of phosphate buffer, pH 7.2, maintained at 37 ⁇ 0.5° C.
  • the formulation is such that less than 20%, or less than 15%, or less than 10% (or in other embodiments, less than 1%, 3%, 5% or 7%) of the total drug loaded into the formulation is released from the formulation prior to activation of the formulation by a specified condition which triggers a substantially greater rate of release.
  • release triggers include, for example, a change in pH and/or swelling of the polymer by hydration and/or contact with an enzyme and/or heating of the formulation. Such heating can for example make use of one of the means described above.
  • the formulation may release drug quickly as a bolus, or steadily over a period of time.
  • the total loaded drug may release at least 50% (or 30%, 60% or 75%) of the total loaded drug over a period of not more than 1, 3, 5, 7, 10, 20, 30, 45, 60, 120 or 360 minutes following activation.
  • substantially all the drug may be released over a very short period of time, such as not more than 1, 2 or 3 minutes, or in other embodiments where longer release is desired, over a period of not more than 30 minutes.
  • the rapid melting characteristic of CYSC polymers is used to provide formulations which can be administered in the body and transported to a targeted disease site with little or no release of the drug during transport, but which can be triggered to release the drug at the site by targeted radiation which melts the CYSC polymer at the site.
  • targeted radiation which melts the CYSC polymer at the site.
  • a large dose of a drug can be delivered specifically at the target site when needed. This is particularly useful when dealing with toxic drugs that are best delivered in a site-specific manner and not systemically. Site-specific delivery also reduces the dose needed.
  • Such drugs include cytotoxic agents such as chemotherapeutics.
  • the external source of radiation may be, for example, a focused beam of radiation, e.g. infra-red (IR) or radiation of a similar wavelength.
  • the radiation source may have a wavelength of about 400-1500 nm, e.g. 500-1200 nm or 700-1100 nm.
  • This heat-induced release mechanism may be particularly useful in embodiments wherein the formulation is targeted to a specific site prior to release of the drug.
  • Such embodiments include formulations to target tumour tissue whereby, upon heating, a chemotherapeutic agent is released locally, providing a concentrated bolus of drug at the target site, but minimizing systemic exposure.
  • a chemotherapeutic agent such as carboplatin may be formulated with a CYSC polymer and a targeting ligand such as an antibody or folate that binds selectively to a cell surface receptor differentially expressed on the surface of a specific type tumour cell, for example a colon cancer cell.
  • the formulation may for example be formulated as an emulsion and delivered orally. The emulsion will pass through the stomach and gut to the colon where it will preferentially adhere to tumour tissue. Excess formulation will be voided. An infra-red (IR) source will be used to target the tumour site, heating the adhered formulation and releasing the Carboplatin at high concentration to the target site. Little or none of the drug will be released from the formulation until the formulation is heated.
  • IR infra-red
  • This method of administration reduces the amount of drug delivered systemically and thereby reduces the damaging effects of toxic drugs on healthy cells.
  • a material which can be heated by radiation e.g. carbon nanotubes
  • a similar embodiment might employ venous delivery of a liquid or emulsion formulation wherein the drug formulation specifically binds to a target at any location reachable by the circulation.
  • Initial burst release of a drug is often (but not always) undesirable, and the present invention provides a reduced burst effect due to the interactions between the drug and the crystalline side chains of the polymeric carrier material.
  • the formulation of the invention releases a drug so that the initial release of drug does not exceed the upper threshold of the therapeutic window. In other embodiments it exceeds the upper therapeutic window threshold for no more than 1 hour (or alternately no more than 2, 3, 4, 5, or 6 hours).
  • the formulation of the invention releases a drug so that the maximum initial release of drug does not exceed by more than 50% the mean rate of release of drug (the mean rate measured over a period from 3-12 hours post administration). Alternatively the maximum initial release of drug does not exceed by more than 20% or 30% or 40% or 70% or 100% the mean rate of release of drug as measured over a period from 6-24 hours or 1-12 hours or 12-48 hours post administration.
  • a formulation of the invention may be implanted directly into a subject to provide acceptable burst effect and sustained release. But for some formulations, and particularly with some particularly toxic drugs that have a narrow upper limit to their therapeutic window, pre-treatment of the formulation may be done to reduce burst effect in vivo. Pre-treatment may simply involve soaking the formulation in a biocompatible liquid or elution buffer, for example phosphate buffered saline (PBS) or water for a period of time before implantation.
  • PBS phosphate buffered saline
  • the solid polymer formulation would be removed from its packaging, and placed in the elution buffer for, for example 30 minutes to an hour. In some embodiments longer soaking times may be desirable, for example overnight.
  • Soaking may continue for any duration, for example for up to (or alternatively not more than) 1, 3, 6, 9, 12, 24 or 46 hours.
  • This period of soaking will allow the formulation to equilibrate with its liquid environment and will provide some degree of hydration (if hydration does occur) such that and drug that has migrated to the surface, or any drug that would provide a burst release when implanted into the subject will now be released during the soaking period.
  • the formulation will be implanted into the subject to provide sustained release of the drug within a therapeutic window.
  • the formulation is provided as part of a kit, wherein the kit comprises a two-chamber blister pack having the formulation in a first chamber and a liquid (an elution buffer, e.g. PBS) in a second chamber, and wherein an operator can break the seal between the first and second chambers allowing the liquid to contact the formulation.
  • the formulation is per-treated in the liquid for a period of time, for example from 30 minutes to 2 hours to allow any burst to dissipate.
  • the formulation is then removed aseptically from the packaging and implanted into the recipient subject, for example implanted subcutaneously by use of a simple trocar.
  • Temperature or pH changes may be used to induce drug release at a desired time and/or location.
  • a small increase in the temperature of the formulation, in situ in an mammal or cell for example from body temperature to a temperature above body temperature, but below a temperature which would damage the mammal or cell around the formulation, causes the CYSC polymer to melt, so that it changes from a crystalline to an amorphous structure.
  • the combination of the loss of crystallinity, and in the case of a hydrogel, loss in volume, are factors which are useful in the delivery of the drug.
  • Focused infrared radiation can be applied from outside the body to selectively heat a target within the body.
  • a formulation may be delivered to a particular location within a patient without appreciable release of drug.
  • an IR beam can be used to heat the target, causing a bolus release of drug at the desired location and time.
  • One such embodiment uses a formulation that includes a ligand that binds specifically to a target.
  • ligands may be, for example, antibodies, and are discussed further herein.
  • the formulation is delivered to the patient, for example intravenously; the ligand allows the formulation to bind to and accumulate at a target, such as cancer tissue; a focused IR beam is applied to the target tissue, thereby releasing a bolus of drug.
  • Another method of promoting the release of a drug associated with a CYSC polymer inside a human body or other mammal or cell is to supply heat to the CYSC polymer, for example through one or more of a hot compress, hot water, hot contact wand, hot pad, infrared radiation, and penetrating heat via near infrared radiation; and/or by generating heat within the formulation.
  • the formulation can include a component which will generate heat when exposed to electromagnetic radiation of a particular range of wavelengths.
  • Such components include for example carbon fiber nanotubules or particles which absorb near-IR light in the range of about 700-1100 nm, silver particles or gold particles.
  • a transdermal formulation may be applied to the skin and heat may be produced by chemical or electrical means, or even by physical means such as rubbing with the hand to produce friction-induced heat, to provide a bolus release of drug. Such embodiments are further described herein.
  • the formulations may include a remotely controlled release mechanism to trigger release of the drug, e.g., an electromechanical mechanism that allows an operator to release drug by use of a radio-frequency signal, sent, for example, over a computer network such as the Internet or a hospital intranet.
  • a remotely controlled release mechanism to trigger release of the drug
  • an electromechanical mechanism that allows an operator to release drug by use of a radio-frequency signal, sent, for example, over a computer network such as the Internet or a hospital intranet.
  • Such a mechanism may employ, for example, solenoids, electromagnetic gates or other microfluidic flow control mechanisms.
  • a remotely operated heating element may be provided to heat the formulation and thus release a bolus of drug.
  • a therapeutically effective dose of the drug may be released at a predetermined time wherein the drug is released from the formulation by one or more of the following changes in condition (i) heating the formulation, (ii) hydration of the formulation, (iii) exposing of the formulation to an enzyme, or (iv) changing the pH of the environment surrounding the formulation.
  • compositions and devices of the invention include lozenges, capsules, tablets, pills, pessaries, lavages, suppositories, inhalable powders, creams, solutions, suspensions, oral suspensions, emulsions, micelle systems, nanoparticles, vesicles, nanocapsules, microcapsules, microparticles, microspheres, microparticles, particles, hydrogels, pills, tablets, including sub-lingual tablets, depots and injectables.
  • Hydrogels are sometimes a preferred form in that they can be mixed as a powder with the drug in a solvent medium to hydrate the hydrogel/drug mixture.
  • Sustained release formulations will need to reside in or on the body for the period of desired release, therefore such formulations will be implants, implanted devices and patches, for example transdermal, or transmucosal. Pills, capsules and syrups are typical for oral/gastro-intestinal formulations that are resistant to acid degradation. Because of their susceptibility to acid or severe environments, polypeptides and proteins are often administered by injection as suspensions or solutions. Topical application of other drugs will typically be in suspension or cream form.
  • Diseases that may be treated by the formulations of this invention include, but are not limited to, cardiac diseases, cardio-vascular diseases, neoplastic diseases, inflammation and all diseases associated with the inflammatory process such as arthritis, auto-immune diseases such as lupus, allergies, infectious diseases (viral, bacterial, fungal, protozoan and prion), endocrine diseases such as diabetes, obesity and all forms of weight-related diseases and disorders whether clinically significant or not, hypertension, psychosis, anxiety, depression or any psychological disease, addiction, erectile dysfunction or any sexual dysfunction, blood-lipid diseases such as high cholesterol, Alzheimer's, alopecia, propecia, mange, incontinence, pain, Meniere's disease, migraine, tinnitus, osteoperosis, fertility problems and any other disease of an mammal or cell for which administration of a drug is warranted.
  • cardiac diseases such as cardio-vascular diseases, neoplastic diseases, inflammation and all diseases associated with the inflammatory process such as arthritis, auto-imm
  • Mammal or cells that can be treated by the present invention include for example human beings and other mammals, including bovines, primates, equines, ovines, porcines, canines and felines, and also birds, fish, ungulates, bovines, primates, equines, ovines, porcines, canines and feline animals.
  • a formulation of the invention is coated onto an implantable medical device.
  • implanted devices include stents, pacemakers, catheters, screws, staples, sutures, prosthetic devices etc.
  • Such devices can be made by applying the formulation to an interior or exterior surface of a device by dipping, painting, spraying, misting, rolling, or other method. In some methods, the formulation is heated to above its melting temperature and applied to the device and then dried to form a solid coating.
  • the devices are implanted depots such as solid, liquid and gelatinous depots that can be deposited into the tissue of a subject, for example by subcutaneous injection.
  • the formulation is heated to above its melting temperature and injected (or otherwise flowed) into the desired location, e.g. subcutaneously, where it cools and forms a depot which will then release drug in situ.
  • Tp is only just above body temperature, e.g. less than 55° C., preferably less than 48° C., so that the formulation may be implanted with minimal discomfort or tissue damage.
  • the formulation cools and crystallizes.
  • Such an application may be of particular use in providing an implanted device that moulds to fit the internal shape of a cavity such as within an ablated area of an infracted heart, within bone tissue or subdermally.
  • the formulation includes a non-polymeric substance, e.g. sucrose acetate isobutyrate (SAIB) and non-water soluble liquid materials having a viscosity of at least 5,000 centipoise at 37° C. that do not crystallize neat under ambient physiological conditions, for example those described in U.S. Pat. No. 6,992,065 (Okumu) which is hereby incorporated by reference in its entirely for all purposes.
  • SAIB sucrose acetate isobutyrate
  • non-water soluble liquid materials having a viscosity of at least 5,000 centipoise at 37° C. that do not crystallize neat under ambient physiological conditions, for example those described in U.S. Pat. No. 6,992,065 (Okumu) which is hereby incorporated by reference in its entirely for all purposes.
  • SAIB sucrose acetate isobutyrate
  • Such substances for example SAIB, which are preferably highly hydrophobic, can enhance drug loading and/or modify
  • devices include a formulation containing a radio-opaque dye or other marker so that the formulation can be imaged by fluoroscopy or X-ray.
  • a radio-opaque dye or other marker so that the formulation can be imaged by fluoroscopy or X-ray.
  • Many radio-opaque substances are commonly known and used such as barium, silver and gold.
  • the CYSC polymer may be loaded with one or more hydrophilic or hydrophobic drugs, for example, a small molecule, polypeptide, protein, carbohydrate, polynucleotide, nucleoside, siRNA, immunoglobulin of Fc or Fab fraction thereof, a cyclic compound, alkaloid, beta-lactam, or other antibiotic.
  • hydrophilic or hydrophobic drugs for example, a small molecule, polypeptide, protein, carbohydrate, polynucleotide, nucleoside, siRNA, immunoglobulin of Fc or Fab fraction thereof, a cyclic compound, alkaloid, beta-lactam, or other antibiotic.
  • the drug may also be an agonist or antagonist of neurotransmitters, an antipsychotic (for example fluphenazine maleate, chlorpromazine, chlorpromazine hibenzoate, sulpiride, carpipramine hydrochloride, carpipramine maleate, clocapramine hydrochloride, mosapramine hydrochloride, Risperidone (or any compound containing functional groups of benzisoxazole and/or piperidine), clozapine, oranzapine and sertindole); or an SSRI; or it may comprise cell signalling molecules such as cytokines such as lymphokines, monokines, chemokines, interleukins, prostoglandins etc a statin, a Cox-2 inhibitor, an SSRI, a calcium channel blocker, psychotropic drug, bisphosphonate, anti-proliferative, mitotic inhibitor, angiogenic factor, antangiogenic factor, small molecule such as rapamycin or derivatives, or almost
  • Specific drugs and drug classes include ibuprofen, uracils (e.g., 5-fluorouracil), steroids and esters of steroids or other hormones (e.g., estrogen, progesterone, testosterone, androsterone, cholesterol, norethinidrone, digoxigenin, cholic acid, deoxycholic acid, and chenodeoxycholic acid), boron containing compounds (e.g., carborane), chemotherapeutic nucleotides, drugs (e.g., antibiotics, antivirals, antifungals), enediynes (e.g., calicheamicins, esperamicins, dynemicin, neocarzinostatin chromophore, kedarcidin chromophore), heavy metal complexes (e.g., cisplatin, carboplatin), hormone antagonists (e.g., tamoxifen), non-specific (non-antibody) proteins (e
  • a selection of some important drugs that can be incorporated into and delivered by the formulations of the invention includes the following: Hydro- Name Trade Name Drug Class M r /Da phobic Atorvastatin Lipitor Statin 1,209 YES Symvastin Zocor Statin 418 YES Celecoxib Celebrex Cox-2 inhibitor 381 YES Sertradine Zoloft SSRI 343 YES Omeprazole Losec/Prilosec PPI 345 YES Esomeprazole Nexium PPI 767 YES (isomer of Prilosec) Pravastatin Pravachol Statin 447 NO Azithromycin Zithromax Antibiotic 749 NO Quetiapine Seroquel SSRI 883 YES Metoprolol Seloken/Toprol ⁇ -blocker 653 NO Budesonide Pulmicort/ anti-inflammatory- 431 YES Rhinocort steroid Clarithromycin Biaxin Antibiotic 748 YES Paroxetine Paxil
  • hormones such as growth hormones or sex hormones, secreted proteins, alpha-glucosidase, erythropoietin, antibody drug conjugates, Fc fusion proteins, interferon, anti-CD20 therapeutics, Factor VIII, IX or X, insulin or calcitonin.
  • hormones such as growth hormones or sex hormones, secreted proteins, alpha-glucosidase, erythropoietin, antibody drug conjugates, Fc fusion proteins, interferon, anti-CD20 therapeutics, Factor VIII, IX or X, insulin or calcitonin.
  • chemotherapeutic agents used to kill neoplastic cells are incorporated into the formulations.
  • Such chemotherapeutic agents include the following: 1) Alkylating agents, which destroy the cancer cell's DNA. E.g., Busulfan, Cyclophoshamide and Melphalan. 2) Nitrosureas, that inhibit a cancer cell's enzymes needed for DNA repair. E.g., Carmustine and Lomustine. 3) Anti-metabolites, that interfere with both a cancer cell's DNA and RNA. E.g., 5-Fluorouracil, Methotrexate and Fludarabine. 4) Anti-tumor antibiotics that interfere with a cancer cell's DNA in addition to changing its cellular membrane.
  • E.g., Bleomycin, Doxorubicin and Idarubicin are examples of Antitumor Antibiotics.
  • Mitotic Inhibitors that inhibit enzymes needed for protein synthesis in the cancer cell.
  • Radioactive isotopes which destroy cancer cells by the production of radioactive emissions.
  • Drugs with well-known sustained release applications include, for example, anti-pain medications (e.g. morphine analogues), anti-psychotics (e.g. risperidone), anti-inflammatories (e.g. steroids or NSAIDs such as Budesonide), hormones (e.g. testosterone or progesterone) cholesterol lowering drugs (e.g., statins), osteoporosis drugs (biphosphonates), anti-angeogenics (e.g., anti-VEGF) and contraceptives.
  • anti-pain medications e.g. morphine analogues
  • anti-psychotics e.g. risperidone
  • anti-inflammatories e.g. steroids or NSAIDs such as Budesonide
  • hormones e.g. testosterone or progesterone
  • cholesterol lowering drugs e.g., statins
  • osteoporosis drugs e.g., osteoporosis drugs (biphosphonates)
  • Any derivative (defined herein as including, but not limited to any pharmacologically active metabolite, or analogue, agonist, derivative, variant, congener, or isomeric form) of any drug described herein can equally be used; and any formulation described is intended to encompass formulations comprising such derivatives.
  • the crystalline side chain polymer incorporates ligands that bind specifically to target receptor molecules.
  • Target receptor molecules are present on the surface of a specific type of target cell, such as a cancer cell.
  • the ligands may be incorporated into the polymer formulation by copolymerization of a comonomer which carries a receptor covalently attached to the monomer.
  • a ligand may be incorporated into the formulations of the invention by any other means not involving covalent bonds such as mixing which allows the ligand to associate with the polymer either as a simple physical mixture, or by ionic bonds, hydrogen bonds, Van der Waal's forces or hydrophobic/hydtrophilic interactions.
  • the ligands bind specifically to molecules expressed on the cell surface of a target e.g., receptor proteins that are differentially over-expressed on target cells, for example cancerous cells.
  • folate receptors For example, many types of cells express a large number of folate receptors on their cell surface, more so than for non-cancerous cells. Folic acid or derivatives or portions of folate can be physically mixed during preparation of the formulation, or added to the outside of particles formed after crystallization or precipitation of the formulation.
  • the folate molecules bind specifically with the folate receptors on a target cancer cell.
  • a chemotherapeutic agent for example carboplatin or cis-platin or taxol, can be mixed with or bound by hydrogen bonding or otherwise to the CYSC polymer, and thereafter delivered to a specific cell target.
  • This ligand-targeted polymeric drug delivery system can be used to deliver any number of known targeted cancer therapy agents in several different classes.
  • small-molecule drugs can be used to block specific enzymes and growth factor receptors (GFRs) involved in cancer cell growth. These drugs act as signal-transduction inhibitors.
  • GFRs growth factor receptors
  • One such drug that may be used with the invention is Gleevec® (STI-571 or imatinib mesylate) to treat gastrointestinal stromal tumours and certain kinds of chronic myeloid leukemia.
  • Iressa® ZD1839
  • This drug targets the epidermal growth factor receptor (EGFR), which is overproduced by many types of cancer cells.
  • Apoptosis-inducing drugs may also be incorporated into the formulation of the invention.
  • One such drug is Velcade® used to treat multiple myeloma. Velcade blocks proteasomes, which help to regulate cell function and growth.
  • Other apoptosis-inducing drugs include GenasenseTM to treat leukemia, non-Hodgkin's lymphoma, and solid tumours. Genasense blocks the production of BCL-2, which promotes the survival of tumour cells.
  • drugs include monoclonal antibodies that bind to growth factor receptors, such as Herceptin® (Trastuzumab).
  • the formulation comprises, a slightly basic/neutral CYSC polymer derived from a mixture of an SCC monomer, hydroxyethyl methacrylate and dimethylaminoethyl methacrylate and a drug, for example, an anti-cancer drug, e.g. methotrexate.
  • folic acid is mixed with the CYSC polymer and the drug or added to the formulation after isolation of the formulation, so as to concentrate folic acid at the surface of the drug formulation particles.
  • Cancer cells have more folate receptor sites on their cell membranes, enabling concentration of the formulation at the cancer cell sites after administration of the formulation.
  • the encapsulated or bound methotrexate Upon exposure to an external heat stimulus, the encapsulated or bound methotrexate is released as the CYSC polymer transitions from a crystalline to an amorphous structure.
  • release of the drug may be stimulated by means other than heat, e.g. by one or more of hydration, swelling, osmotic expulsion and by increasing the permeability of the polymer.
  • ligands are either small proteins (about 30-50 amino acid residues) or have a small active site of only a few residues (often 3-7 amino acids) and can be attached to CYSC polymers as used in this invention, for example covalently.
  • EGFR epidermal growth factor receptor
  • GPCRs G protein-coupled receptors
  • EGFR, GI hormones or any related proteins may be used as specific targets by providing a polymer-drug formulation with a ligand, such as a specific antibody, that binds specifically to EGRF or GI hormones or homologous proteins or portions thereof.
  • a number of leukemias and lymphomas including cutaneous T-cell lymphoma, chronic lymphocytic leukemia, and B-cell non-Hodgkin's lymphoma, express the interleukin-2 receptor (IL-2R) receptor.
  • IL-2R interleukin-2 receptor
  • Antibodies or other ligands e.g., DAB389IL-2, ONTAKTM; Seragen Inc, San Diego, Calif.
  • targeting the interleukin-2 receptor may be used to target a polymer-drug formulation of the invention.
  • Monoclonal antibodies directed against CD33 a cell surface antigen highly expressed in acute promyelocytic leukemia (APL) may be used as a targeting ligand with the present invention against APL tumor cells.
  • APL acute promyelocytic leukemia
  • Rituximab is an anti-cancer monoclonal antibody that binds to CD20 which is expressed on the surface of malignant B cells.
  • Rituximab may be used as a targeting ligand with the present invention.
  • Antibodies and other ligands that bind OPG or RANKL can be used as targeting ligands with the present invention against multiple myeloma tumor cells.
  • folate receptor FR
  • Folate, analogues of folate and other ligands that bind to folate receptors can be incorporated into the formulations of the invention to provide specific and/or preferential targeting of various tumor tissues.
  • PSMA Prostate-specific membrane antigen
  • PCa prostate cancer
  • IGF-I insulin-like growth factor I
  • IGF-II insulin-like growth factor 1 receptor
  • IGF1R insulin-like growth factor 1 receptor
  • IGF2R acts as a cell surface receptor for many proteins relevant to breast cancer biology, including IGF-II. IGF2R could be targeted using sugar moieties and/or polysaccharides attached to the polymers as used by the invention.
  • Ovarian cancer G protein coupled receptor 1 and GPR4, two structurally related receptors are high affinity molecular targets for SPC.
  • Such receptors for phospholipids on tumors would be ideal targets for polymers as used by the invention coupled to lysophosphatidic acid (LPA), sphingosylphosphorylcholine (SPC), and/or phosphatidic acid (PA).
  • LPA lysophosphatidic acid
  • SPC sphingosylphosphorylcholine
  • PA phosphatidic acid
  • Ligands such as phospholipids that bind to these targets may be incorporated into the formulations of the invention to provide specific and/or preferential targeting of ovarian and other tumor tissue.
  • FGF fibroblast growth factor
  • FRS2a fibroblast growth factor receptor substrate 2
  • Anti-FGF antibodies of portions of FRS2 domains may serve as ligands for targeting tumors.
  • PD-L1 Programmed death receptor ligand 1
  • Ligands that bind to PD-L1, such as antibodies or IFN-gamma or related molecules could provide specific and/or preferential targeting of cancer cells and tissues.
  • uPA urokinase-type plasminogen activator
  • CXCR4 is a seven-span transmembrane protein that is a native receptor for the alpha-chemokine stromal-derived factor-1 (SDF-1) that is expressed on the surface of cancer stem cells.
  • SDF-1-CXCR4 axis is also involved in directing their trafficking/metastasis to organs that highly express SDF-1 (e.g., lymph nodes, lungs, liver, and bones).
  • a region of SDF-1 homologous to the receptor-interacting region could be incorporated into the formulations of the invention to provide specific targeting to cancer cells, particularly to treat or prevent metastasis of tumor cells.
  • Notch signalling contributes to pre-malignant metaplastic changes that precede pancreatic carcinoma, and it is also likely to be involved in other forms of metaplasia.
  • the Notch receptor ligand can be incorporated into the formulations of the invention to provide specific targeting to pancreatic carcinoma and other cancer cells.
  • ligands may be incorporated into the formulation of the invention including ligands that recognize Receptor Protein Kinases, G-Protein Coupled Receptors, Nuclear Receptors, Ligand-Gated Receptor Ion Channels, Macrophage Scavenger Receptors, T-Cell Receptors, Netrin Receptors, VPS10 Domain Containing Receptors, Tetraspan Family Proteins, Ion Channels, ABC Transporters, Semaphorins and Neuropilins, Membrane Proteins Associated with Intercellular Communication and Peripheral and Anchored Membrane Proteins.
  • Receptor Protein Kinases G-Protein Coupled Receptors, Nuclear Receptors, Ligand-Gated Receptor Ion Channels, Macrophage Scavenger Receptors, T-Cell Receptors, Netrin Receptors, VPS10 Domain Containing Receptors, Tetraspan Family Proteins, Ion Channels
  • the ligand may be an antibody or portion of an antibody (such as the Fab portion or fragment thereof) that binds specifically to the cancer-associated target molecule.
  • Antibodies may be polyclonal or monoclonal and often may be humanized. Such antibodies can be produced by standard well-known methods. Monoclonal antibodies (MAb's) that bind specifically to tumor-associated antigens have been employed in an attempt to target toxin, radionucleotide, and chemotherapeutic conjugates to tumors. To date, a variety of monoclonal antibodies have been developed that induce cytolytic activity against tumor cells.
  • a humanized version of the monoclonal antibody MuMAb4D5 directed to the extracellular domain of P185, growth factor receptor (HER2), is used to treat human breast cancer.
  • a chimeric antibody against CD20 which causes rapid depletion of peripheral B cells, including those associated with lymphoma, is used to treat low-grade B-cell non-Hodgkin's lymphoma.
  • Other humanized and chimeric antibodies under development or in clinical trials include an anti-CD33 antibody that binds to CD-33, which is expressed on most types of myeloid leukemic cells.
  • the present formulations of the invention may incorporate any target-specific ligands of any kind, including the antibodies and ligands mentioned herein, and any derivatives and homologues thereof.
  • Embodiments of the invention have advantages that result inter alia from the fact that preferred CYSC polymers can comprise a desired balance of hydrophobic and/or hydrophilic moietys which can be selected to associate with a wide range of drugs through chemical and/or physical bonds, thus providing formulations which can be delivered to mammal or cells in a wide variety of ways.
  • the CYSC can have sharp and relatively low melting points; can have a desired molecular weight; do not have any adverse effect on mammal or cells; and can be eliminated from mammal or cells after the drug mixed with the CYSC polymer has been delivered to the mammal or cell.
  • Advantages include 1) The ability of preferred CYSC polymers to be easily mixed and processed with drugs.
  • Risperidone may be physically mixed with a CYSC polymer, or may be pre-associated, for example with a surfactant, PEG, human (or bovine etc) serum albumin, or with proteins etc to provide immunological shielding, increased half-life, and improved bioavailability.
  • the formulation may be formed into a shaped solid implant suitable for introduction, e.g.
  • the current invention may be formulated to supply from 1 to 60 mg/day over a period of 1 to 200 days.
  • the advantage of an implanted dosage form is increased compliance, which with psychosis, is a major issue.
  • at least 50 mg of Risperidone is formulated into a single implantable dosage form by mixing the drug in powdered form with a CYSC polymer at a temperature above the Tm of the polymer, example at between 42° C. and 60° C. No solvent is required.
  • the mixture is cooled and shaped into solid elongated or approximately spherical implants.
  • the amount of Risperidone formulated into a single implantable dosage form may be at least 100 mg, or at least 200 mg, or at least 500 mg, or at least 1000 mg, or at least 1500 mg, or at least 2000 mg. In some dosage forms, the total amount of drug may be up to 3, 4 or 5 grams.
  • the Risperidone implant is introduced subcutaneously into a subject using a trocar.
  • the implant releases Risperidone at an average rate of between 1 and 60 mg (for example no more than 1, 2, 3, 4, 5, 7, 10, 20, 40, 80, 120, 200, or 300 mg) per day over a period of at least 5, 10, 15, 20, 25, 30, 40, 60 or 90 days.
  • the implant releases Risperidone at an average rate of between 4 and 12 mg per day over a period of at least 7 days. During this period, a desired therapeutic effect is provided for at least 75% of the time.
  • the implant is then removed, or may be left in to erode over time. If a larger bolus of drug is desired, the local area of skin above the implant may be heated by any convenient means.
  • the implant releases Risperidone at an average rate of between 1 and 20 mg per day, or 3 and 100 mg per day or 4 and 30 mg per day over a period of at least 7 days or at least 14, 21, 30, 45, 60 or 90 days.
  • Risperidone may be pre-associated with a surfactant, PEG, human serum albumin or with proteins.
  • the CYSC polymer comprises side chains having an average length of, for example, between 6 and 50 monomer units. In another embodiment, the CYSC polymer has side chains with an average length of between about 12 and 50 alkyl ester acrylate or methacrylate monomer units.
  • the proportion of drug to crystalline polymer is between 5% by weight and 30% by weight, or at least 5% by weight, at least 10% by weight, at least 15% by weight, at least 20% by weight, at least 25% by weight, at least 30% by weight, at least 35% by weight, at least 40% by weight, or at least 50% by weight
  • Risperidone is physically mixed with the polymer and no covalent or ionic bonds are formed between the drug and the polymer.
  • the drug associates with the polymer via hydrogen bonds and/or Van der Waals forces.
  • Risperidone is associated with the CYSC polymer by electrostatic bonds, by hydrogen bonds, Van der Waals forces or a combination of one or more of these effects. This exemplary embodiment may be applied to any number or drugs.
  • the drug of the formulation may be an opioid, opioid antagonist, synthetic opioid, morphine, fentanyl or sufentanyl, or any type of local or systemic analgesic acting on peripheral or central nervous pair receptors.
  • the polymer may be implanted under the skin such that the drug is released over a period of time to treat pain for a number of hours such as at least 3, at least 6 or at least 12 hours.
  • the formulation may also be an oral formulation, transdermal formulation or depot.
  • the formulation is part of a transdermal drug delivery device such as a patch, wherein the drug, mixed into the CYSC polymer, is released from a patch placed against the skin.
  • the formulation may be made to release the drug steadily or increasingly or decreasingly over a period of time, or may be made to release drug in intermittent boluses in response to a stimulus such as heat.
  • a drug will not be released immediately as a bolus but will be released from the polymer over time in a generally sigmoid pattern, providing a desired therapeutic delivery, e.g. to treat pain over a desired time, such as over at least 1, at least 3, at least 6 or at least 12, 24, 36, or 48 hours.
  • the drug may be delivered with approximately first order kinetics, over at least a certain desired time (e.g., over at least 1, at least 3, at least 6, or at least 12, 24, 36 or 72 hours).
  • the drug is released from the polymer, and the polymer is not transported across the skin.
  • the release of drug may be induced or increased by the application of heat to the device.
  • the device may be heated by a separate heating device or by an integral heating unit.
  • the amount of drug released from the formulation will depend on the duration of heating and the temperature of the device. Heat-induced drug release may be controlled by the physician, either directly or remotely, or by the patient. This provides controlled self-administration of drug to treat pain and other conditions when needed.
  • the drug released from the formulation may be released onto the surface of the skin, and will then penetrate the skin by various means.
  • transdermal delivery relies on passive diffusion across skin membranes, but penetration may also be improved by using solvents or enhancers such as water, ethanol (EtOH) and l-menthol (LM) that modify the properties of the outermost layers of the skin, or on the use of electrical or thermal technologies to “push” drugs through the skin. Any such means may be used in the present invention, either mixed with the polymer or separate from the polymer. Delivery rates of an opioid such as fentanyl may for example range from about 1.0 to 1000 ng/cm 2 /hr following application of a transdermal patch.
  • a transdermal formulation may be made by mixing the CYSC polymer and drug, optionally with an adhesive component, and retaining the formulation produced in or on a flexible film to produce a patch.
  • the flexible impermeable film forms the backing of the patch, and the formulation side to be applied to the skin may be covered with a removable cover, which is removed prior to application to the skin.
  • the formulation side includes at least some adhesive portion, generally on the periphery of the patch so that when applied, the patch forms a seal against the skin, isolating the formulation from the environment.
  • Such embodiments exclude “gating” devices wherein a drug is maintained in a reservoir and is separated from the skin by a polymer membrane the permeability of which may be altered to allow drug delivery.
  • the present invention does not include a drug reservoir separated from the skin by a polymer firm.
  • the drug is integrally mixed together with the CYSC polymer to form a drug-polymer formulation.
  • Heat may be produced by chemical or electrical means, or even by physical means such as rubbing with the hand to produce friction-induced heat.
  • the heating element may be functionally linked to a control (lock-out) element that prevents activation without permission, such as by use of a radio frequency signal to control the activation of an electrical heat-generating circuit.
  • the CYSC polymers described in the Examples were prepared by solution polymerization of the monomers in IPA at about 80° C. for 3 hours under a nitrogen blanket with 0.1% AIBN. BMP (6%) was used to control the molecular weight under 10,000, e.g. around 5000. IPA was removed under reduced pressure at elevated temperature. At the end of the reduced pressure stage, the internal temperature reached 120-130° C. and, in all the examples except Example 3A, 0.5 g of Trigonox was added. The reaction was continued at 120-130° C. for at least 1 hr, followed by 1 hr under reduced pressure.
  • Example 7A one of the components of the polymer was DMAEA quat, and the polymer was prepared by converting the amine polymer of Example 5A into the quaternary ammonium salt by reaction with dimethyl sulphate in MiBK at 1/1 molar ratio (50-55° C., 3 hours) followed by removal of MiBK under reduced pressure at elevated temperature.
  • the polymer of Example 8A which contains DMAEMA quat, was prepared by converting the amine polymer of Example 6 into the quaternary ammonium salt.
  • Tables 1A, 1B and 1C summarize the preparation and testing of 20 CYSC polymers 1A-20A.
  • the polymers were prepared by the procedure described above, using the monomers, and the molar amounts thereof, shown in line 1 of Tables 1A, 1B and 1C.
  • Lines 2, 3 and 4 in Tables 1A, 1B and 1C show the values of Mw and Mn, and the DSC test results, for each of the 20 polymers.
  • Lines 5 and 6 show shows the behavior of the polymers in four solvents with various polarities at 10% loading at 70° C. and room temperature (RT) respectively.
  • the solubility parameters of the solvents are shown in parentheses in the Table. A typical procedure was to weigh 0.5 g of polymer and 4.5 g solvent into a 20 ml vial, followed by heating in a 70° C. oven for 10 to 15 min. The mixture was shaken by hand while warm.
  • Lines 5, 6 and 7 show respectively (line 5) whether the polymer dissolved at 70° C., (line 6) whether a uniform gel was formed after cooling to room temperature, and (line 7) the calculated solubility parameters of the CYSC polymers.
  • Lines 8 and 9 (Examples 1C-20C) in Tables 1A, 1B and 1C show the results of mixing the polymers with diclofenac sodium (dcl).
  • the mixtures were uniform except when using the polymers of Examples 1A, 5A, 16 A, 17A and 18A.
  • Line 9 shows the results of DSC examination of the uniform mixtures.
  • Line 10 shows the results of preparing gel mixtures containing dcl, CYSC polymer and NMP at Oct. 50, 1950. Eight of the polymers formed uniform gels at RT.
  • Line 11 shows the results of preparing mixtures containing dcl (9.1%), CYSC polymer NMP at the ratio of Oct. 10, 1990.
  • Six of the 20 polymers (8A, 11A, 12A, 13A, 14A and 20A) formed a uniform gel at RT.
  • Examples 1D-20D and 1E-20E demonstrate the effect of NMP on release rate.
  • Lines 12 and 13 show the results of using the 15 polymers which formed uniform mixtures in Examples 1C to 20C, to prepare compositions containing more than 10% of dcl using the same process as in Examples 1C to 20C.
  • dcl/CYSC polymer/IPA in ratios of Feb. 10, 1970 and 3/10/100 respectively were prepared at 70° C.
  • IPA was removed, all the tested CYSC polymers were miscible with dcl at 16.7% and 12 of them at 23.1%.
  • Polymers 6A, 7A and 15A were not miscible and did not yield uniform mixtures.
  • Example 2A The polymer of Example 2A was used to produce uniform dry mixtures having loadings of up to 37.5% of dcl, using the same process as as in Examples C1-C, as shown in Table F1 below.
  • Table H1 summarizes the preparation and testing of 4 CYSC polymers 1H-4H.
  • the polymers were prepared by the procedure described above, using the monomers, and the molar amounts thereof, shown in lines 1 of Table H1.
  • the Mw, Mn and DSC characteristics of the polymers are shown in lines 2, 3 and 4 of Table H1.
  • Line 14 (Examples 11-20I) of Tables 1A, 1B and 1C summarizes the preparation of uniform mixtures of dcl and each of the 5 polymers (1A, 5A, 16A, 17A and 18A) which did not yield uniform mixtures in Examples 1C-20C (in which IPA was used).
  • Uniform 2-phase mixtures were prepared by mixing dcl into the molten polymer at the weight ratio of 1/10 at 50-70° C. using a homogenizer for 1 min. in a vial. During the cooling stage, the vial continued to rotate until the mixture in the vial was solidified.
  • Line 15 (Examples 1J-20J) of Tables 1A, 1B and 1C summarizes the preparation of mixtures of risp and the polymers of Examples 1A-20A by mixing risp, polymer and IPA at the ratio of risp/polymer/IPA of Jan. 10, 1940 at 70° C., followed by removing IPA in a 70° C. oven. The dry mixture was obtained by removing residual IPA under the reduced pressure at 70° C. Only 5 out of the 20 mixtures were uniform. In the uniform mixtures, the polymers were 2A, 3A, 4A, 19A and 20A, all containing carboxylic acid moieties. Line 16 reports the DSC characteristics of the uniform mixtures.
  • Line 17 (Examples 1K-20K) of Tables 1A, 1B and 1C summarizes the preparation of mixtures of risp and the polymers of Examples 1A-20A.
  • the final dry mixtures were obtained by removing residual IPA under reduced pressure at 70° C. Only polymer 3A yielded a uniform mixture at 16.7% loading.
  • compositions containing polymer 3A and a wider range of risperidone loading were prepared using the same process as in Examples 1J-20J. All the resulting mixtures were uniform. When the loading was higher than 25%, the mixture was more viscous and a temperature higher than 70° C. was used to prepare the disk.
  • Line 18 (Examples 1N-20N) of Tables 1A, 1B and 1C summarizes the preparation of uniform two-phase mixtures of risp and each of four polymers (1A, 5A, 16A and 18A) by mixing risperidone powder (0.5 g) into the molten polymer (5 g) at 50-70° C. using a homogenizer for 1 min in a vial. During the cooling stage, the vial continued to rotate until the mixture in the vial was solidified. Since risperidone was not miscible with these 4 polymers, it became uniformly distributed in the CYSC polymer as a discrete phase.
  • Example 1J-20J Five mixtures (2J, 3J, 4J, 19J and 20J) from Example 1J-20J were subjected to a hand grinding process to generate powder, and then passed through a 450 micron filter screen. Mixture 19J was sticky and agglomerated. Test articles for the release of risperidone from these particles were prepared by confining 0.5 gram of powder in a wine-bottle-shaped wire mesh (200 ⁇ 200 wires per linear inch—an opening of about 75 micron). The resulting article was then placed in the bottom of a 20 ml vial, ready for a release test.
  • Such a thin disk was prepared to speed up the risperidone release as well as probe the effect of temperature triggering on release rate. Once the temperature triggering conditions were established, 0.5 g scale discs were prepared using the same methods in Examples 1J-20J and the dynamic temperature triggered release tests were performed using the conditions established in Examples 1P-20P
  • a uniform two-phase mixture was obtained by mixing Polymer 20A with Bovine serum albumin (BSA, Fraction V, 99% from Aldrich, 66,000 Daltons).
  • BSA Bovine serum albumin
  • the BSA was mixed into the molten polymer at 50-70° C. using a homogenizer for one minute in a vial. During the cooling stage, the vial continued to rotate until the mixture in the vial was solid. Since BSA was not miscible with polymer 20A at the molecular level, it became uniformly distributed in the CYSC polymer as discrete phase.
  • Example 20Q The procedure of Example 20Q was followed, but replacing the BSA by Leuprorelin powder, which, like BSA, was not miscible with the polymer at the molecular level and was uniformly distributed in the CYSC polymer as a discrete phase.
  • Lines 19 and 20 summarize the preparation of mixtures of pravastatin sodium (9.1%) and the polymers of Examples 1A-20A, using the same method as in Examples 1J-20J. There was no phase separation in any of the mixtures. The DSC characteristics of the mixtures are shown in line 20.
  • Lines 21 and 22 summarize the preparation of mixtures of dexamethasone (9.1%) and the polymers of Examples 1A-20A, using the same method as in Examples 1J-20J. Only the mixtures containing polymers 3A and 19A showed no phase separation in any of the mixtures. The DSC characteristics of those mixtures are shown in line 22.
  • Lines 23 and 24 (Examples 1T-20T) of Tables 1A, 1B and 1C summarize the preparation of mixtures containing dexamethasone (9.1%).
  • dexamethasone 9.1%.
  • uniform two-phase mixtures were prepared by mixing each of polymers 2A, 4A, 7A, 10A, 17A, 18A and 20A with dexamethasone powder.
  • the dexamethasone was added to the molten polymer at 50-70° C. at a wt ratio of 1/10 using a homogenizer for 1 min. in a vial.
  • the vial continued to rotate until the mixture in the vial was solidified. Since dexamethasone was not miscible with these 7 polymers at the molecular level, it became uniformly distributed in the CYSC polymer as discrete phase.
  • Line 24 shows the DSC characteristics of the mixtures.
  • Polymers 2U, 3U, 4U and 20U contain the same ingredients as polymers 2A, 3A, 4A and 20A respectively and were prepared in the same manner except for additional post treatment to remove residual monomers.
  • an additional 0.25% AIBN was used before IPA was removed, followed by 2 washes with methanol.
  • additional 0.25% AIBN, 0.5% L575 and 0.5% T42S was used to reduce the residual monomer.
  • polymer 20U an additional 0.25% AIBN was used before IPA was removed, followed by 2 washes with DI water.
  • the Mw, Mn and the DSC characteristics of the polymers are in Table U1.
  • polymers 2U, 3U, 4U and 20U were converted into cylindrical articles (diameter 6 mm, length 20 mm) containing 9.1% risperidone.
  • the articles were sterilized by cobalt radiation at greater than 25 KGy.
  • Lines 25 and 26 summarize the preparation of mixtures of Tacrolimus (9.1%) and the polymers of Examples 1A-20A.
  • the mixtures were prepared by mixing tacrolimus with the polymer in IPA at a ratio of 1/10/40 at 50-70° C., followed by removal of IPA in a 70° C. oven.
  • the final dry mixture was obtained by removing residual IP a under reduced pressure at 70° C. All the dry mixtures were uniform.
  • Line 26 shows the DSC characteristics of the dry mixtures.
  • the final dry drug/polymer mixtures were obtained by removing residual IPA under reduced pressure at 70° C. It was found that 8 out of the 20 mixtures of diclofenac sodium with polymers in examples 31-40 yielded uniform mixtures. Polymers that yielded uniform mixtures with diclofenac sodium were #22, #24, #26, #27 #28, #29, #33 and #35. It was observed that uniform drug/polymer mixtures remained amorphous.
  • Pluronic F127, F68 and F38 were also acquired as controls against CYSC polymers related to controlled release of risperidone from BASF Corporation. These polymers are also main chain crystalline polymers with melting temperatures of 56° C., 54° C. and 49° C., respectively, based on 2 nd heating by DSC at 10° C./min. Mixtures in Table Ex41-51b were also prepared in the same manner as 1C-20C and were uniform. Diclofenac sodium is not miscible with all three polymers (#49, #50 and #51).
  • Examples 52 to 67 represent the controlled release profiles of diclofenac sodium using the 15 uniform mixtures in examples 1C-20C and are labelled as 330-91-XX, where the numbers XX correspond to the numbers in examples 1C-20C.
  • FIGS. C 1 , C 2 and C 3 show the cumulative release of diclofenac sodium in buffer solution with pH of 7.4.
  • Examples 68 to 75 represent the controlled release profiles of diclofenac sodium using the 8 uniform mixtures in examples 1D-20D and are labelled as 330-108-XX, where the numbers XX correspond to the numbers in examples 1D-20D.
  • FIG. D 1 shows the cumulative release of diclofenac sodium.
  • Examples 76 to 81 represent the controlled release profiles of diclofenac sodium using the 6 uniform mixtures in examples 1E-20E and are labelled as 330-109-XX, where the numbers XX correspond to the numbers in examples 1E-20E.
  • FIG. E 1 shows the cumulative release of diclofenac sodium. Sustained release is no longer exist in Examples 76-81 due to the addition of larger amount of NMP
  • Examples 82 to 115 represent the controlled release profiles of diclofenac sodium using all the uniform mixtures in examples 1F-20F and are labelled as 332-23-XX and 332-24-XX for 16.7% and 23.1% loading, where the numbers XX correspond to the polymer numbers in examples 1A-20A and 336-R4-Y, where the number Y correspond to the number in Tables F1.
  • FIGS. F 1 , F 2 and F 3 show the cumulative release of diclofenac sodium at 16.7% loading.
  • FIGS. F 4 and F 5 show the cumulative release of diclofenac sodium at 23.1% loading.
  • FIG. F 6 summarizes the release profile of up to 37.5% diclofenac sodium from polymer 2A.
  • the release IDs 336-R4-1 to -336-R4-7 corresponds to 2F1 to 2F7 in Table F1.
  • Examples 116-118 represent the controlled release profiles of diclofenac sodium using the 3 uniform mixtures in examples G1-G4 and are labelled as 336-7-X, where the number X corresponds to the number in Table G1.
  • FIG. G 1 summarizes the release profile of diclofenac sodium from mixtures of 2A with 3A, 4A and 20A, as well as from single polymers 2A, 3A, 4A and 20A as comparison.
  • Examples 119-122 represent the controlled release profiles of diclofenac sodium using the 4 uniform mixtures of examples H1-H4 and are labelled as 336-8R8-X, where the number X corresponds to the numbers in Table H1.
  • FIG. H 1 summarizes the release profile of diclofenac sodium from polymers with higher Tm.
  • Examples 123-127 represent the controlled release profiles of diclofenac sodium using the 5 uniform 2 phase mixtures in Tables 1A, 1B & 1C in examples 1I-20I and are labelled as 336-2R2-X, where the number X corresponds to the polymer numbers in Table A1.
  • FIG. I 1 summarizes the release profile of diclofenac sodium.
  • Examples 128 to 132 represent the controlled release profiles of risperidone using the 5 uniform mixtures in examples 1J-20J and are labelled as 330-117-XX, where the numbers XX correspond to the numbers in Tables 1A, 1B &1C.
  • FIG. J 1 shows the release profile of risperidone from the mixtures of 9.1% risperidone in 5 polymers.
  • Examples 133 to 139 represent the controlled release profiles of risperidone using all the 7 uniform mixtures in examples 1K-20K and are labelled as 336-5-X, where the number X corresponds to the numbers 3K1 to 3K7 in Table K1.
  • FIG. K 1 shows the cumulative release of up to 37.5% risperidone from polymer 3A.
  • Examples 140-142 represent the controlled release profiles of risperidone using the 3 uniform mixtures in examples 1L-20L and are labelled as 336-R6-X, where the number X corresponds to the numbers L1 to L4 in Table L1.
  • FIG. L 1 summarizes the release profile of risperidone from mixtures of 2A with 3A, 4A and 20A, as well as from single polymers 2A, 3A, 4A and 20A as comparison.
  • Examples 143-146 represent the controlled release profiles of risperidone using the 4 uniform mixtures H1 to H4 in Table H1 in examples 1M-20M and are labelled as 336-R9-X, where the number X corresponds to the polymer numbers H1 to H4 in Table H1.
  • FIG. M 1 summarizes the release profile of risperidone from polymers with higher Tm.
  • Examples 147-150 represent the controlled release profiles of risperidone using the 4 uniform 2 phase mixtures in examples 1N-20N and are labelled as 336-3R3-X, where the number X corresponds to the numbers in Tables 1A, 1B &1C.
  • FIG. N 1 summarizes the release profile of risperidone from the 4 polymers.
  • Examples 151-154 represent the controlled release profiles of risperidone from polymers 2A, 3A, 4A and 20A in powder form in examples 1O-20O and are labelled as 335-31-XX, where the number XX corresponds to the number for the polymer IDs in Tables 1A, 1B &1C.
  • FIG. O 1 summarizes the release profile of risperidone from the 4 polymers.
  • Examples 155 to 156 represent the controlled release profiles of risperidone from polymer 2A in examples 1P-20P as 0.05 gram scale thin discs at 37° C. and 60° C.
  • the release IDs are labelled as 330-135-2 and 332-3-2 at 37° C. and 60° C., respectively.
  • FIG. P 1 summarizes the release profile of risperidone from polymer 2A as 0.05 gram scale thin disc at 37° C. and 60° C.
  • Examples 157 and 163 represent the controlled release profiles of risperidone from polymer 2A in examples 1P-20P as 0.5 gram scale thicker discs than examples 155-156 at 37° C. and 60° C. bath at selected times and/or days.
  • the release IDs were labelled as 332-27-XX.
  • FIG. P 3 summarizes the another version of the temperature triggered release profiles of risperidone from polymer 2A by exposing the 0.5 gram thick discs in buffer solution at pH of 5.5 to 60° C. bath every other day for 0 (for temperature switch OFF position) and 60 min (for temperature switch ON position) and the remaining of time at 37° C.
  • the release ID was labelled as 332-45-1,2,3.
  • FIG. P 4 summarizes the 3rd version of the temperature triggered release profiles of risperidone from polymer 2A by exposing the 0.5 gram thick discs in buffer solution at pH of 5.5 to 60° C. bath every other 2 days for 0 (for temperature switch OFF position) and 60 min (for temperature switch ON position) and the remaining of time at 37° C.
  • the release ID was labeled as 332-45-4,5,6.
  • FIG. Q 1 summarizes static pH triggered release profiles of BSA from polymer 20A in these buffer solutions at 37° C.
  • the release IDs are labelled as 334-19-20, 334-20-20 and 334-21-20 for release in pH 7.4, 5.5 and 2.5 buffer solution, respectively.
  • FIG. Q 2 summarizes the dynamic pH triggered release profile of BSA from polymer 20A in dynamic pH buffer solutions at 37° C. The release IDs were labelled as 334-52-20.
  • FIG. R 1 summarizes both static and dynamic pH triggered release profile of Leuprorelin from polymer 20A at 37° C.
  • the release IDs were libelled as 336-1-X, where the numbers X corresponds to the examples IDs in Tables 1A, 1B &1C.
  • the release and sampling conditions are the same as in examples 1C-20C.
  • the release IDs are labelled as 336-35-XX, where the numbers XX correspond to examples IDs in Tables 1A, 1B &1C.
  • the release and sampling conditions are the same as in examples 1C-20C.
  • the release IDs are libelled as 336-35-XX, where the numbers XX correspond to examples IDs in Tables 1A, 1B &1C.
  • the release and sampling conditions are the same as in examples 1C-20C.
  • Examples 189 to 196 represent the controlled release profiles of diclofenac sodium using the 8 uniform mixtures in examples 21A-40A and are labelled as 332-7-XX, where the numbers XX correspond to polymers IDs in Table Ex21-40.
  • FIG. Ex 21 A- 40 A shows the cumulative release of diclofenac sodium in example 21A-40A.
  • Examples 197-204 represent the controlled release profiles of diclofenac sodium using the 4 uniform mixtures in examples 41-51 and are labelled as 332-4-XX, where the numbers XX correspond to polymers IDs shown in FIG. Ex 41 - 51 a .
  • Examples 205-207 represent the controlled release profiles of risperidone using the 3 uniform mixtures in examples 41-51 and are labelled as 332-75-X, where the number X corresponds to polymers IDs shown in FIG. Ex 41 - 51 b .
  • Examples 206-210 represent the in-vivo release profiles of risperidone, and are shown in FIGS. Y 1 to Y 5 .
  • FIG. Y 1 shows the in-vivo Control release profile.
  • FIGS. Y 2 to Y 5 show the risperidone in-vivo release from each of the identified polymers.
  • the sustained release properties of the polymers of the invention were evaluated in a healthy Sprague-Dawley rat subcutaneous (SC) implantation model. Implants were prepared as described below and were loaded with risperidone. Briefly, four different types of implants were prepared and evaluated: Group #2 (336-19-2), Group #4 (336-19-3), Group #3 (336-19-4), and Group #20 (336-19-20). In addition, implants devoid of the drug substance were prepared and evaluated as well: Group #6 (336-20-2) and Group #7 (336-20-20). A total of 10 replicates of each implant test article were provided, four of which were randomly selected for single implantation per animal. All systems were stored at room temperature before and after completion of the implantation.
  • risperidone solution was prepared at a drug concentration of 0.27 mg/mL in phosphate buffer pH 5.5 containing 0.01% w/v Tween-80, filtered through 0.45 microm polycarbonate membrane. The solution was injected SC at 0.2 mg/kg without additional dilutions.
  • JVC jugular vein cannulated
  • Sprague Dawley rats weighing approximately 300 g at study initiation (Hilltop Lab Animals, Scottdale, Pa.) were defined.
  • Surgical implantation of Landec's devices were performed on rats under light anesthesia. The implants were briefly rinsed with a PBS solution pH 7.4 with a single rinse and were inserted SC space of the rats.
  • Blood (0.3 mL) samples were collected at specified time intervals as described in the Table above and were placed into labeled Microtainer® tubes with EDTA as an anti-coagulant.
  • the heparin blood samples were centrifuged, transferred into labeled Eppendorf® tubes and frozen at ⁇ 80° C. and were assayed by a validated LC-MS assay for riperidone and 9-hydroxy-risperidone.
  • the animals were euthanized according to testing facility Standard Operating Procedures, followed by terminal bleeds via cardiocentesis.
  • Device-implanted rats underwent gross necropsy while the tissue was scored macroscopically for irritation, erythema, edema using an established scale.
  • results represent total risperidone in plasma, including both the parent compound and the active metabolite (9-hydroxy-risperidone).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US12/448,033 2006-12-05 2007-12-04 Drug delivery Abandoned US20100210792A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/448,033 US20100210792A1 (en) 2006-12-05 2007-12-04 Drug delivery

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87323406P 2006-12-05 2006-12-05
PCT/US2007/024909 WO2008070118A1 (en) 2006-12-05 2007-12-04 Drug delivery
US12/448,033 US20100210792A1 (en) 2006-12-05 2007-12-04 Drug delivery

Publications (1)

Publication Number Publication Date
US20100210792A1 true US20100210792A1 (en) 2010-08-19

Family

ID=39492556

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/999,415 Expired - Fee Related US8956602B2 (en) 2006-12-05 2007-12-04 Delivery of drugs
US12/448,033 Abandoned US20100210792A1 (en) 2006-12-05 2007-12-04 Drug delivery
US12/746,178 Active US8524259B2 (en) 2006-12-05 2008-12-03 Systems and methods for delivery of materials

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/999,415 Expired - Fee Related US8956602B2 (en) 2006-12-05 2007-12-04 Delivery of drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/746,178 Active US8524259B2 (en) 2006-12-05 2008-12-03 Systems and methods for delivery of materials

Country Status (7)

Country Link
US (3) US8956602B2 (ja)
EP (2) EP2500015A1 (ja)
JP (1) JP2010511713A (ja)
AU (1) AU2007328207A1 (ja)
CA (1) CA2670749A1 (ja)
IL (1) IL198911A0 (ja)
WO (2) WO2008070118A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546412B2 (en) * 2011-12-21 2013-10-01 Abbott Cardiovascular Systems, Inc. Methods of treating heart failure

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2650819A1 (en) * 2006-05-11 2007-11-22 Air Products And Chemicals, Inc. Personal care compositions containing functionalized polymers
US20090011017A1 (en) * 2007-07-05 2009-01-08 Basf Se Polymers based on water-soluble monoolefinic comprising colloidal silica and their use as matrix polymers for solid dosage forms
ES2768224T3 (es) 2007-08-17 2020-06-22 Purdue Research Foundation Conjugados ligando-enlazador de unión a PSMA y métodos para su uso
US8114883B2 (en) * 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
KR101707791B1 (ko) * 2008-09-30 2017-02-17 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 리스페리돈 전달용 이식형 장치
WO2010045598A2 (en) * 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8603532B2 (en) * 2008-10-20 2013-12-10 Massachusetts Institute Of Technology Nanostructures for drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CN102365109B (zh) 2009-01-29 2015-06-03 弗赛特影像4股份有限公司 后段给药
AU2010254816A1 (en) * 2009-06-04 2011-12-08 Landec Corporation Compositions and methods for delivery of materials
US9233063B2 (en) * 2009-12-17 2016-01-12 Air Products And Chemicals, Inc. Polymeric compositions for personal care products
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011105724A2 (ko) * 2010-02-24 2011-09-01 주식회사 티이바이오스 관절연골 재생용 지지체 및 이의 제조방법
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US8370120B2 (en) * 2010-04-30 2013-02-05 Abbott Cardiovascular Systems Inc. Polymeric stents and method of manufacturing same
JP6063382B2 (ja) 2010-08-05 2017-01-18 フォーサイト・ビジョン フォー・インコーポレーテッド 治療薬を眼の埋め込み体へと注入するためのシステム
HUE057267T2 (hu) 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
WO2012019139A1 (en) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2013003620A2 (en) 2011-06-28 2013-01-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
CA2842039A1 (en) * 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
PT2755600T (pt) 2011-09-16 2021-04-19 Forsight Vision4 Inc Aparelhos de troca de fluidos
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP2015515530A (ja) 2012-04-18 2015-05-28 アローヘッド リサーチ コーポレイション インビボ核酸送達のためのポリ（アクリラート）ポリマー
US20140121750A1 (en) * 2012-10-31 2014-05-01 Cook Medical Technologies Llc Fixation Process For Nesting Stents
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
JP6385423B2 (ja) 2013-03-28 2018-09-05 フォーサイト・ビジョン フォー・インコーポレーテッド 治療物質送達用の眼移植片
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2924360C (en) 2013-10-18 2022-04-26 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN104744643B (zh) * 2013-12-25 2018-01-12 中国石油化工集团公司 一种梳型聚合物、制备方法及应用
EP2994175A1 (en) 2014-02-04 2016-03-16 Abbott Cardiovascular Systems, Inc. Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
MY182497A (en) 2014-07-15 2021-01-25 Forsight Vision4 Inc Ocular implant delivery device and method
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
AU2015301054B2 (en) 2014-08-08 2020-05-14 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
AU2015301399B2 (en) * 2014-08-14 2018-11-08 Brown University Compositions for stabilizing and delivering proteins
EP3212709B1 (en) * 2014-10-27 2022-04-13 Borealis AG Polymer composition and cable with advantageous electrical properties
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016187498A1 (en) * 2015-05-21 2016-11-24 Isp Investments Inc. Functionally versatile amphiphilic copolymers
US20170082625A1 (en) * 2015-09-17 2017-03-23 University Of Miami Method and system for microfilter-based capture and release of cancer associated cells
JP6777390B2 (ja) * 2015-10-30 2020-10-28 株式会社日本触媒 生体適合性医療用材料
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
EP3394093B1 (en) 2015-12-23 2022-01-26 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
MA43587A (fr) 2016-01-10 2018-11-14 Modernatx Inc Arnm thérapeutiques codant pour des anticorps anti-ctla-4
MX2018012021A (es) 2016-04-05 2019-01-24 Forsight Vision4 Inc Dispositivos de administracion de farmacos oculares implantables.
US10773008B2 (en) * 2016-08-08 2020-09-15 Universiti Brunei Darussalam Medicated patch for preventing exit site infections during peritoneal dialysis
US11458107B2 (en) * 2016-08-25 2022-10-04 The Regents Of The University Of California Abiotic anti-VEGF nanoparticle
CA3059993A1 (en) * 2017-04-12 2018-10-25 Inscent, Inc. Arthropod pest control compositions, kits and uses thereof
JP7158143B2 (ja) * 2017-04-13 2022-10-21 株式会社日本触媒 生体適合性医療用材料
JP6819435B2 (ja) * 2017-04-20 2021-01-27 住友電気工業株式会社 樹脂組成物及び電線
WO2018213361A1 (en) * 2017-05-15 2018-11-22 Vanderbilt University LONG-CIRCULATING ZWITTERIONIC POLYPLEXES FOR siRNA DELIVERY
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
WO2018232006A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding coagulation factor viii
KR20200059254A (ko) * 2017-09-25 2020-05-28 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 친수성 약물을 함유하는 점안액으로부터의 방부제 제거
CA3082891A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
MA50803A (fr) 2017-11-22 2020-09-30 Modernatx Inc Polynucléotides codant pour l'ornithine transcarbamylase pour le traitement de troubles du cycle de l'urée
WO2019104160A2 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
JP7424976B2 (ja) 2017-11-22 2024-01-30 モダーナティエックス・インコーポレイテッド プロピオン酸血症の治療用のプロピオニルＣｏＡカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US20220110966A1 (en) 2018-09-02 2022-04-14 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
MA53608A (fr) 2018-09-13 2021-07-21 Modernatx Inc Polynucléotides codant pour les sous-unités e1-alpha, e1-beta et e2 du complexe alpha-cétoacide déshydrogénase à chaîne ramifiée pour le traitement de la leucinose
WO2020056147A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
MA53615A (fr) 2018-09-14 2021-07-21 Modernatx Inc Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar
WO2020069169A1 (en) 2018-09-27 2020-04-02 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
WO2020206277A1 (en) * 2019-04-04 2020-10-08 The Regents Of The University Of Colorado, A Body Corporate Methods and devices for reducing intraocular oxidative damage
EP3965797A1 (en) 2019-05-08 2022-03-16 AstraZeneca AB Compositions for skin and wounds and methods of use thereof
EP3969053A4 (en) * 2019-05-15 2023-01-11 The University of Chicago LACTATE RESPONSE SYSTEM AND METHODS
MX2019014545A (es) * 2019-12-04 2021-06-07 Univ Mexico Nac Autonoma Proceso de obtencion de nanoparticulas de polimero para la liberacion de farmacos mediada por receptor.
CN115397374A (zh) 2019-12-19 2022-11-25 特清公司 从滴眼剂中去除防腐剂
US11635148B2 (en) 2019-12-27 2023-04-25 Horizon Healthcare LLC Tube clamp
US11674617B2 (en) 2019-12-27 2023-06-13 Horizon Healthcare LLC Tube lock
EP4158005A1 (en) 2020-06-01 2023-04-05 ModernaTX, Inc. Phenylalanine hydroxylase variants and uses thereof
JP2022071659A (ja) 2020-10-28 2022-05-16 パナソニックＩｐマネジメント株式会社 芳香徐放性を有する植物繊維含有複合樹脂成形体
WO2022104131A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
JP2024512026A (ja) 2021-03-24 2024-03-18 モデルナティエックス インコーポレイテッド オルニチントランスカルバミラーゼ欠損症の治療を目的とした脂質ナノ粒子及びオルニチントランスカルバミラーゼをコードするポリヌクレオチド
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022266083A2 (en) 2021-06-15 2022-12-22 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
CN114231042B (zh) * 2021-12-17 2022-08-30 北京化工大学 一种接枝共聚物及其载药组合体与制备方法
WO2023130008A2 (en) * 2022-01-01 2023-07-06 Sea Pharmaceuticals Llc Pharmaceutical compositions of 6-(2-(2h-tetrazol-5-yl)ethyl)decahydroisoquinoline-3-carboxylic acid and derivatives thereof
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608549A (en) * 1970-01-15 1971-09-28 Merrill Edward Wilson Method of administering drugs and capsule therefor
JPS5436828B2 (ja) * 1974-08-16 1979-11-12
CA1170070A (en) 1981-05-01 1984-07-03 Robert J. Quint Temperature controlled release composition
US4558690A (en) * 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
NL194389C (nl) 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
GB8417810D0 (en) 1984-07-12 1984-08-15 Graham N B Temperature/fluid sensitive devices
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
JPS6242918A (ja) 1985-08-20 1987-02-24 Kaken Pharmaceut Co Ltd 持続性製剤
US4808412A (en) 1987-06-11 1989-02-28 Eastman Kodak Company Rumen-stable compositions
US4830855A (en) * 1987-11-13 1989-05-16 Landec Labs, Inc. Temperature-controlled active agent dispenser
DE3825211A1 (de) * 1988-07-25 1990-02-01 Henkel Kgaa Verbesserte koerperresorbierbare knochenwachse (iii)
US5156911A (en) * 1989-05-11 1992-10-20 Landec Labs Inc. Skin-activated temperature-sensitive adhesive assemblies
ATE142557T1 (de) * 1989-05-11 1996-09-15 Landec Corp Von der temperatur aktivierte bindemitteleinheiten
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
JP2920956B2 (ja) 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
US5129180A (en) * 1990-12-07 1992-07-14 Landec Labs, Inc. Temperature sensitive seed germination control
US5665822A (en) * 1991-10-07 1997-09-09 Landec Corporation Thermoplastic Elastomers
US5120349A (en) * 1990-12-07 1992-06-09 Landec Labs, Inc. Microcapsule having temperature-dependent permeability profile
US6524274B1 (en) * 1990-12-28 2003-02-25 Scimed Life Systems, Inc. Triggered release hydrogel drug delivery system
DE69225586T2 (de) * 1991-02-12 1999-01-28 Landec Corp Temperaturzonen spezifische druckempfindliche klebmittelzusammensetzungen, klebmittelgebinde und damit verbundene verfahren zu ihrer benutzung
EP0544097A1 (de) * 1991-10-23 1993-06-02 Boehringer Ingelheim Kg Halbfeste Mischungen aus Oligomeren und/oder Polymeren auf der Basis von Milchsäure, Verfahren zur deren Herstellung und deren Verwendung als resorbierbare Implantate
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
US5429654A (en) * 1992-04-30 1995-07-04 Exxon Research & Engineering Co. Coated agricultural products
IT1260154B (it) * 1992-07-03 1996-03-28 Lanfranco Callegaro Acido ialuronico e suoi derivati in polimeri interpenetranti (ipn)
US5469867A (en) * 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
BR9307130A (pt) 1992-09-28 1999-03-30 Zeneca Ltd Composição de polímero polímero cristalizável processo para preparar e fabricar a composição para fabricar uma estrutura de polímero e para remover de uma fase fluida um composto de solubilidade limitada em água mas difundível na mesma artigo conformado e uso da composição
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
JPH07157424A (ja) * 1993-12-03 1995-06-20 Lintec Corp 局所麻酔用ゲル製剤
DE4424267C2 (de) * 1994-07-09 1996-07-11 Hewlett Packard Gmbh Vorrichtung zur kontinuierlichen Erfassung von Blutparametern
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6831116B2 (en) * 1995-03-07 2004-12-14 Landec Corporation Polymeric modifying agents
US6255367B1 (en) * 1995-03-07 2001-07-03 Landec Corporation Polymeric modifying agents
US5662711A (en) * 1995-06-07 1997-09-02 Douglas; William Flow adjustable artery shunt
RU2092161C1 (ru) 1995-06-23 1997-10-10 Санкт-Петербургская Государственная Химико-Фармацевтическая Академия Средство с регулируемым высвобождением пентоксифиллина
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
DE19545327C2 (de) 1995-12-05 2001-04-19 Fraunhofer Ges Forschung Verfahren zur Herstellung von hydrophobierten resorbierbaren Polyestern und deren Verwendung
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
SE506983C2 (sv) * 1996-07-02 1998-03-09 Akzo Nobel Nv Ortoesterbaserad polymer, förfarande för dess framställning och användning därav
US6199318B1 (en) * 1996-12-12 2001-03-13 Landec Corporation Aqueous emulsions of crystalline polymers for coating seeds
US6540984B2 (en) * 1996-12-12 2003-04-01 Landec Corporation Aqueous dispersions of crystalline polymers and uses
US5852117A (en) * 1997-08-26 1998-12-22 National Starch And Chemical Investment Holding Corporation Process for making lactide graft copolymers
US6583251B1 (en) * 1997-09-08 2003-06-24 Emory University Modular cytomimetic biomaterials, transport studies, preparation and utilization thereof
US5895404A (en) * 1997-09-29 1999-04-20 Ruiz; Carlos E. Apparatus and methods for percutaneously forming a passageway between adjacent vessels or portions of a vessel
US5945457A (en) * 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
DE19753298A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US5919484A (en) 1998-01-15 1999-07-06 Isp Investments Inc. Controlled release, drug-delivery tableted composition including a polymer of a vinyl amide, (meth)acrylic acid, a long chain alkyl (meth)acrylate and a lower alkyl (meth)acrylate
CA2324254C (en) 1998-03-18 2005-01-04 University Technology Corporation Sustained-release composition including amorphous polymer
DE19811919A1 (de) * 1998-03-18 1999-09-23 Basf Ag Verwendung von Copolymerisaten monoethylenisch ungesättigter Carbonsäuren als Solubilisatoren
DE69926017T2 (de) * 1998-04-27 2005-12-22 SurModics, Inc., Eden Prairie Bioaktive Wirkstoffe freisetzende Beschichtungen
CN1207090C (zh) * 1998-04-27 2005-06-22 陶氏化学公司 包囊化活性材料
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6730322B1 (en) * 1998-04-30 2004-05-04 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
US6319521B1 (en) * 1999-02-10 2001-11-20 University Technology Corporation Microparticles of lactide-co-glycolide copolymers and methods of making and using the same
DE19908753C2 (de) 1999-02-20 2003-10-02 Jenapharm Gmbh Bioabbaubare, injizierbare Oligomer-Polymer-Zusammensetzung
US6297337B1 (en) * 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6352667B1 (en) * 1999-08-24 2002-03-05 Absorbable Polymer Technologies, Inc. Method of making biodegradable polymeric implants
US7101928B1 (en) * 1999-09-17 2006-09-05 Landec Corporation Polymeric thickeners for oil-containing compositions
US6569128B1 (en) * 1999-09-22 2003-05-27 Advanced Infusion Corporation Catheter with adjustable flow restrictor
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
AU2098901A (en) * 1999-12-13 2001-06-18 Michigan State University Process for the preparation of polymers of dimeric cyclic esters
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
CN1419446A (zh) 2000-01-27 2003-05-21 田边制药株式会社 缓释制剂及其制法
AU1667701A (en) * 2000-02-10 2001-08-16 Rohm And Haas Company Bioadhesive composition
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
KR100452972B1 (ko) 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
US6679605B2 (en) * 2000-05-22 2004-01-20 Medennium, Inc. Crystalline polymeric compositions for ophthalmic devices
US20060286064A1 (en) * 2000-08-30 2006-12-21 Medivas, Llc Therapeutic polymers and methods
US6858634B2 (en) * 2000-09-15 2005-02-22 Monsanto Technology Llc Controlled release formulations and methods for their production and use
JP2002138033A (ja) * 2000-10-30 2002-05-14 Shiseido Co Ltd 抗アクネ用皮膚外用剤
EP1334143B1 (en) * 2000-11-16 2007-02-14 Biocompatibles UK Limited Polymers and polymerisation processes
US20020106406A1 (en) * 2000-12-08 2002-08-08 Mchugh Anthony J. Crystallizable/non-crystallizable polymer composites
GB0100761D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6656385B2 (en) * 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
DE10113302B4 (de) * 2001-03-19 2009-09-24 Fraunhofer-Gesellschaft für die angewandte Forschung e.V. Verfahren zur Herstellung von Homo- und Copolyestern der Milchsäure
US20020134012A1 (en) * 2001-03-21 2002-09-26 Monsanto Technology, L.L.C. Method of controlling the release of agricultural active ingredients from treated plant seeds
FR2823450B1 (fr) * 2001-04-12 2004-08-27 Rhodia Chimie Sa Suspension obtenue a partir d'une emulsion multiple comprenant un compose hydrophobe solide a temperature ambiante et granules obtenus par sechage de la suspension
US7030127B2 (en) * 2001-06-29 2006-04-18 Ethicon, Inc. Composition and medical devices utilizing bioabsorbable polymeric waxes
US6967234B2 (en) * 2002-12-18 2005-11-22 Ethicon, Inc. Alkyd-lactone copolymers for medical applications
US6815181B2 (en) * 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
WO2003011226A2 (en) * 2001-08-01 2003-02-13 Smithkline Beecham Corporation Products and drug delivery vehicles
US8303651B1 (en) * 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US6951642B2 (en) * 2001-09-28 2005-10-04 3M Innovative Properties Company Water-in-oil emulsions with anionic groups, compositions, and methods
AU2002337803A1 (en) 2001-10-03 2003-04-14 Glaxo Group Limited Sustained release pharmaceutical compositions
GB0125216D0 (en) * 2001-10-19 2001-12-12 Univ Strathclyde Dendrimers for use in targeted delivery
US20030082217A1 (en) * 2001-10-25 2003-05-01 Isabelle Afriat Use of heat-stabilizing microcapsules to improve the activity or penetration of cosmetic or pharmaceutical active principles
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US6964778B1 (en) * 2002-09-06 2005-11-15 Health Research, Inc. Temperature controlled content release from liposomes
US7378479B2 (en) 2002-09-13 2008-05-27 Lubrizol Advanced Materials, Inc. Multi-purpose polymers, methods and compositions
GB0221942D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Drug delivery
GB0221941D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US6866860B2 (en) * 2002-12-19 2005-03-15 Ethicon, Inc. Cationic alkyd polyesters for medical applications
US20040120981A1 (en) 2002-12-20 2004-06-24 Aruna Nathan Crosslinked alkyd polyesters for medical applications
US20040254419A1 (en) * 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
UY28326A1 (es) 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
WO2005039489A2 (en) * 2003-09-24 2005-05-06 Polymerix Corporation Compositions and methods for the inhibition of bone growth and resorption
KR20060114338A (ko) * 2003-10-28 2006-11-06 노벤 파머수티컬즈, 인코퍼레이티드 경피 약물 전달 장치
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
EP1729741A2 (en) 2004-03-03 2006-12-13 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
WO2006002399A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable implantable medical devices, methods and systems
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US20060034891A1 (en) * 2004-08-12 2006-02-16 Laurie Lawin Biodegradable controlled release bioactive agent delivery device
US9011831B2 (en) 2004-09-30 2015-04-21 Advanced Cardiovascular Systems, Inc. Methacrylate copolymers for medical devices
CA2611081C (en) 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
WO2007002184A1 (en) * 2005-06-21 2007-01-04 Bausch & Lomb Incorporated Drug delivery device having zero or near zero-order release kinetics
WO2007035942A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal risperidone delivery system
US7579429B2 (en) * 2005-12-16 2009-08-25 Board Of Trustees Of Michigan State University Cyclic alkyl substituted glycolides and polylactides therefrom
US20070259584A1 (en) * 2006-05-04 2007-11-08 Ronald Whitehouse Biodegradable polymer composites and related methods
US20090124996A1 (en) * 2006-11-03 2009-05-14 Scott Heneveld Apparatus and methods for injecting high viscosity dermal fillers
US20090198183A1 (en) * 2006-11-03 2009-08-06 Krumme John F Apparatus and methods for injecting dermal fillers
WO2008066657A2 (en) 2006-11-03 2008-06-05 Aesthetic Sciences Corporation Compositions, devices and methods for modifying soft tissue
WO2009086250A1 (en) * 2007-12-21 2009-07-09 Aesthetic Sciences Corporation Self-contained pressurized injection device

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546412B2 (en) * 2011-12-21 2013-10-01 Abbott Cardiovascular Systems, Inc. Methods of treating heart failure

Also Published As

Publication number Publication date
WO2008070118A1 (en) 2008-06-12
EP2500015A1 (en) 2012-09-19
US8956602B2 (en) 2015-02-17
JP2010511713A (ja) 2010-04-15
EP2101745A4 (en) 2009-12-30
WO2008070118A9 (en) 2008-09-18
US20110009571A1 (en) 2011-01-13
CA2670749A1 (en) 2008-06-12
EP2101745A1 (en) 2009-09-23
WO2008070165A1 (en) 2008-06-12
US8524259B2 (en) 2013-09-03
AU2007328207A1 (en) 2008-06-12
US20080269105A1 (en) 2008-10-30
IL198911A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
US8956602B2 (en) Delivery of drugs
US8399007B2 (en) Method for formulating a controlled-release pharmaceutical formulation
EP2229150B1 (en) Systems and methods for delivery of materials
US20090263346A1 (en) Systems and methods for delivery of drugs
JP6134788B2 (ja) 疎水性組成物のための生分解性薬物送達
Alexander et al. Poly (ethylene glycol)–poly (lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications
Zentner et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs
JP2021107420A (ja) 埋込み型薬物送達組成物およびその使用法
CN104822370A (zh) 包含治疗剂的治疗性纳米颗粒及其制备和使用方法
JP2010519183A (ja) 生理溶液の溶出のためのタンパク質の沈殿を用いる重合
JP6203224B2 (ja) 局所投与部位における医薬組成物の保持改善のための組成物および方法
EP3331495B1 (en) Liquid polymer delivery system for extended administration of drugs
KR20080105820A (ko) 약물 방출 스텐트용 코팅제, 그의 제조방법 및 이 코팅제로코팅된 약물 방출 스텐트
US20200316265A1 (en) Multiphase gel
WO2016020697A1 (en) Pharmaceutical compositions of polymeric nanoparticles
CN116133642A (zh) 包含聚合物组合制备剂的制备剂和组合物
US10251955B1 (en) Heparin-mimicking sulfonated reverse thermal gel for the delivery of heparin-binding therapeutic proteins
WO2023064830A1 (en) Erdafitinib formulations and systems for intravesical administration
KR102354882B1 (ko) 친수성 제1 블록, 소수성 제2 블록, 및 티올과 특이적으로 결합할 수 있는 작용기를 포함하는 블록 공중합체
WO2007132205A2 (en) Nanoparticle pharmaceutical carrier
Alvarez-Lorenzo et al. Poly (ethylene oxide)-poly (propylene oxide) block copolymer micelles and gels in drug delivery: state-of-the-art and future perspectives
Chen Novel delivery systems for hormones

Legal Events

Date Code Title Description
AS Assignment

Owner name: LANDEC CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAFT, DAVID, DR.;BITLER, STEVEN, DR.;ZHENG, QIANG, DR.;AND OTHERS;SIGNING DATES FROM 20080412 TO 20080425;REEL/FRAME:023140/0327

AS Assignment

Owner name: LANDEC CORPORATION, CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ONE APPLICATION PREVIOUSLY RECORDED (NO. 60837234 "WIDGET DISTRIBUTION") SHOULD BE DELETED. IT WAS ACCIDENTLY ADDED. PREVIOUSLY RECORDED ON REEL 023140 FRAME 0327. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:TAFT, DAVID, DR.;BITLER, STEVEN, DR.;ZHENG, QIANG, DR.;AND OTHERS;SIGNING DATES FROM 20080412 TO 20080425;REEL/FRAME:023193/0368

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION